Health considerations for transgender women and remaining unknowns: a narrative review

Sean J. Iwamoto, Justine Defreyne, Micol S. Rothman, Judith Van Schuylenbergh, Laurens Van de Bruaene, Joz Motmans and Guy T’Sjoen

Abstract: Transgender (trans) women (TW) were assigned male at birth but have a female gender identity or gender expression. The literature on management and health outcomes of TW has grown recently with more publication of research. This has coincided with increasing awareness of gender diversity as communities around the world identify and address health disparities among trans people. In this narrative review, we aim to comprehensively summarize health considerations for TW and identify TW-related research areas that will provide answers to remaining unknowns surrounding TW’s health. We cover up-to-date information on: (1) feminizing gender-affirming hormone therapy (GAHT); (2) benefits associated with GAHT, particularly quality of life, mental health, breast development and bone health; (3) potential risks associated with GAHT, including cardiovascular disease and infertility; and (4) other health considerations like HIV/AIDS, breast cancer, other tumours, voice therapy, dermatology, the brain and cognition, and aging. Although equally deserving of mention, feminizing gender-affirming surgery, paediatric and adolescent populations, and gender nonbinary individuals are beyond the scope of this review. While much of the data we discuss come from Europe, the creation of a United States transgender cohort has already contributed important retrospective data that are also summarized here. Much remains to be determined regarding health considerations for TW. Patients and providers will benefit from larger and longer prospective studies involving TW, particularly regarding the effects of aging, race and ethnicity, type of hormonal treatment (e.g. different oestrogens, anti-androgens) and routes of administration (e.g. oral, parenteral, transdermal) on all the topics we address.

Keywords: anti-androgen, oestradiol, gender-affirming hormone therapy, gonadotropin-releasing hormone agonist, safety, transgender women

Introduction

In 2016, several groups published priorities for transgender (trans) health and research with a focus on collaboration and overcoming health disparities among this population.1–2 Despite the increasing presence of gender diversity in both mainstream media and medical literature, many barriers to optimal health among trans people still exist. For example, the Report of the 2015 United States (US) Transgender Survey3 showed that healthcare coverage for trans people in the US remains precarious, with 25% of those who sought coverage for hormones in 2014 being denied and 23% of respondents not seeing a doctor out of fear of mistreatment as a trans person. Similarly, in Europe, a 2012 European Union Agency for Fundamental Rights survey found that 22% of trans respondents felt personally discriminated against by healthcare personnel because of their trans identity.4 Many providers,
including specialists, do not feel adequately trained to care for trans patients, which may result in patients seeking alternatives to the standard transition-related options that are described in international guidelines.

Trans people can experience social, hormonal or surgical transition depending on their level of self-acceptance and availability of support and resources. Gender-affirming hormone therapy (GAHT) is often an important aspect of transition-related care, improving quality of life (QOL) and mental health of trans people. Gender-affirming hormone therapy (GAHT) should be accessible to, but not required of, all trans people. In this narrative review, we aim to provide readers with a comprehensive summary of health considerations related to TW, defined here as people assigned male at birth (AMAB) but who have female gender identity or expression. We also aim to identify areas to focus our research in order to answer the many questions that remain surrounding TW’s health.

We acknowledge that trans terminology is evolving. Though used with the best inclusive intention, terms and phrases to describe trans study populations may still be limited in definition. For example, some may use the phrase, ‘trans people AMAB’, to be inclusive of TW and gender nonbinary people, individuals who do not identify as strictly male or female. For the sake of consistency throughout this narrative review, we will use the abbreviation ‘TW’ to refer to a ‘trans woman’ or ‘trans women’. Table 1 contains additional terminology that will be used.

**Part 1: feminizing GAHT**

The recently updated Endocrine Society guidelines provide recommendations for feminizing GAHT for TW (Table 2). The World Professional Association for Transgender Health (WPATH) Standards of Care (SOC), version 7, The Center of Excellence for Transgender Health at the University of California, San Francisco and additional reviews also provide summaries of these feminizing hormonal treatments. Typical feminizing GAHT includes oral, transdermal and parenteral oestradiol formulations in addition to anti-androgens [e.g. spironolactone, cyproterone acetate (CPA) and gonadotropin-releasing hormone agonists (GnRHas)]. Oestrogens and anti-androgens suppress serum testosterone levels and block androgen action, and it is expected that testosterone levels will decline on all forms of treatment. Transdermal oestradiol patches or gel (and depending on availability, parenteral oestradiol injections) may be safer with regard to triglycerides and clotting risk than oral oestradiol by bypassing first-pass hepatic metabolism.

Transdermal oestradiol use has been proposed and implemented particularly in older TW (e.g. age >40 years). We are unaware of any randomized controlled trials (RCTs) comparing oral, transdermal and parenteral oestradiol or the various anti-androgens in TW.

Oestrogens not in the guidelines have caveats to their use. Conjugated equine oestrogens cannot be accurately measured in current serum oestradiol assays, making dose adjustments difficult based on serum oestradiol level. Addressed particularly in the cardiovascular disease (CVD) section, oral ethinyl oestradiol is no longer recommended due to the associated increased risks of blood clots and cardiovascular (CV) morbidity and mortality. We are unaware of specific studies looking at the safety and efficacy of sublingual and pellet formulations of oestradiol.

Other anti-androgens proposed by the Endocrine Society guidelines are the GnRHAs, which are well tolerated with satisfactory results. Since some centres now use them as first-line therapy to suppress endogenous gonadotropins [follicle-stimulating hormone (FSH) and luteinizing hormone (LH)] and testosterone in TW, it is increasingly important to know about a TW’s history of puberty suppression. For example, administration of GnRHAs in early puberty can lead to underdevelopment of the penis, which can compromise future vaginoplasty. If GnRHAs are initiated as part of GAHT after secondary sexual characteristics are established, those pubertal changes do not regress. Gava and colleagues reported on CPA and leuprolide acetate being equally effective in the suppression of gonadotropins and testosterone after 12 months. We are unaware of any long-term outcome studies in TW who underwent pubertal suppression with GnRHAs, stressing the importance of this as a research focus.

Alternative anti-androgen therapies exist that have not yet been substantiated for routine use by supporting research. Progesterone is discussed in the breast development section, but we do not recommend its routine use in TW until more...
rigorous studies demonstrate potential benefits outweigh any risks. Some references mention finasteride and dutasteride, 5-alpha reductase inhibitors, as single agents for individuals seeking partial feminization of with persistent virilized features after complete androgen blockade or orchiectomy. These medications block the conversion of testosterone to dihydrotestosterone but can actually raise serum testosterone levels, although it is unclear whether this has deleterious effects on feminization. Data on bicalutamide, an androgen receptor antagonist used in the treatment of prostate cancer, in TW are nonexistent, but Neyman and colleagues recently published on bicalutamide’s feminizing effects (particularly breast development) in AMAB trans adolescents. Another recent study in cisgender (cis) women, with polycystic ovary syndrome (PCOS) showed some improvement in hirsutism when bicalutamide was added to an oral contraceptive pill (OCP). It should be noted, however, that bicalutamide has been associated with an increase in liver enzymes.

When barriers prevent trans people from obtaining GAHT from a licensed medical provider, they may search for other sources. Previous reports stated that 4.7–24% of TW have obtained hormones

| Term/phrase | Definition |
|-------------|------------|
| Cisgender (cis) [e.g. cis women, cis men] | People whose gender identity and gender expression align with their sex assigned at birth (SAB) [i.e. not transgender] |
| Gender dysphoria | The distress and unease associated with gender incongruence. The phrase ‘gender identity disorder’ is no longer used, particularly after the 2013 American Psychiatric Association’s DSM-5 replaced it with ‘gender dysphoria’ |
| Gender expression | The external manifestations of a person’s gender. May or may not conform to the socially defined behaviours and external characteristics that are historically referred to as masculine or feminine (e.g. clothing, haircut, jewellery, social interactions, speech patterns) |
| Gender identity | The innate and internal sense of gender that is not visible to other people |
| Gender incongruence | When a person’s gender identity or gender expression differs from that person’s SAB or what is typically associated with the designated SAB. Not everyone with gender incongruence has gender dysphoria or seeks treatment |
| Gender nonbinary | People who may identify and present themselves as both or alternatively male and female, as neither male nor female, or as a gender outside the male/female binary. May include gender-fluid, pan-gender, polygender |
| Gender-affirming hormone therapy (GAHT) | Hormonal treatment that some people may take for their bodies and mind to align with their experienced gender identity |
| Gender-affirming surgery (GAS) | Surgery that some people may undergo for their bodies and mind to align with their experienced gender identity |
| Sex assigned at birth (SAB) | Refers to SAB, which in most countries is restricted to either female (assigned female at birth; AFAB) or male (assigned male at birth; AMAB), relating to genitalia, reproductive organs, sex chromosomes or hormones |
| Transgender (trans) | An adjective that encompasses people whose gender identity or gender expression differs from their SAB; independent of the decision whether to use GAHT or undergo GAS, and inclusive of gender nonbinary people. The terms ‘transgendered’ and ‘transgenders’ should not be used |
| Trans man/trans male/trans masculine | Generally, refers to a person who was AFAB but whose gender identity or gender expression is (more) male/masculine |
| Trans woman/trans female/trans feminine | Generally, refers to a person who was AMAB but whose gender identity or gender expression is (more) female/feminine |
Anecdotally, some TW who utilize services at the Ghent University Hospital Transgender Infopunt have admitted to using OCPs obtained from their female partners. The use of GAHT obtained from nonmedical sources varies from 23% in a United Kingdom sample of trans people referred to a gender clinic,47 to 26.8% in a community-based questionnaire in people who self-identified as trans in Canada,45 to 48.0% in a Belgian sample of trans sex workers 44 and as high as 63% in urban groups of TW in New York City.46 It is important to ask patients about nonprescribed medications in a nonjudgmental fashion with the overall goal of patient and provider shared decision-making regarding the risks and benefits of GAHT.

In summary, guideline-recommended feminizing GAHT incorporates bioidentical oestradiol, unlike ethinyl oestradiol, and anti-androgens to facilitate desired feminization in TW. While these oestrogens and anti-androgens are used off-label, studies have demonstrated their efficacy in suppressing endogenous testosterone levels and promoting feminization. Future research is needed in order for TW and their providers to better individualize GAHT: (1) RCTs to determine which route of oestradiol and type of anti-androgen are most effective; (2) predictors of feminization based on individual TW baseline characteristics; (3) long-term effects of pubertal suppression across the rest of a TW’s lifespan; and (4) reducing barriers to access to GAHT among TW. Additionally, there is a growing population of gender nonbinary patients who were AMAB but desire feminizing hormones even though they do not identify as TW. We need more studies in gender nonbinary patients to see how taking the feminizing GAHT discussed above affects their health outcomes, which doses are most appropriate for nonbinary goals and whether these outcomes are similar to those in TW.

### Part 2: benefits associated with GAHT

#### QOL and mental health

Research on QOL in trans people has previously been published in reviews6,13 and a meta-analysis.48 In studies with a cross-sectional design, it appeared that trans people receiving GAHT had higher overall as well as physical and mental QOL scores49–51 and better mental and general health compared with controls.12,52,53 Trans people not receiving GAHT experienced more limitations in work and other activities due to mental health problems (which reflected in lower emotional Short Form-36 scores) than controls.12,52 In addition, the initiation of GAHT results in an increase

---

### Table 2. Feminizing gender-affirming hormone therapy for trans women.

| Class          | Route of administration | Name of drug                          | Recommended dosing            |
|----------------|-------------------------|---------------------------------------|--------------------------------|
| Oestrogen      | Oral                    | 17-beta oestradiol or oestradiol valerate | 2–6 mg/day                     |
|                | Transdermal             | Oestradiol patch                       | 0.025–0.2 mg/day               |
|                |                         | Oestradiol gel*                        | 2–4 mg/day                     |
|                | Parenteral [intramuscularly] | Oestradiol valerate or cypionate       | 5–30 mg/2 weeks; 2–10 mg/week |
| Anti-androgen  | Oral                    | Spironolactone                         | 100–300 mg/day [Divided twice a day] |
|                |                         | Cyproterone acetate                    | 25–50 mg/day                   |
| GnRH agonist   | Parenteral [subcutaneously] | Leuprolide acetate                     | 3.75 mg/month; 11.25 mg/3 months |
|                |                         | Goserelin acetate                      | 3.6 mg/month                   |

Note: Adapted from Hembree and colleagues.18

*Estradiol gel is not currently in the Endocrine Society guidelines but has been published as a route of administration for patients in studies of the European Network for the Investigation of Gender Incongruence.17,32–35
of overall QOL scores. However, receiving GAHT is not the only factor influencing QOL in TW, as partnership status, social support from family, employment status, levels of hope and undergoing gender-affirming surgery (GAS) contribute to increased QOL. On the other hand, depression, anxiety, poorer education, unemployment, financial dependence, a history of negative healthcare experiences, lack of practical or social support, desiring but not being able to affirm the legal gender, insecurity about one’s own appearance, sleeping problems and illicit drug use are associated with decreased QOL. Although gender-affirming care contributes to improved QOL in trans people, studies calculating a possible gain in quality-adjusted life years are limited, and an incremental cost-effectiveness ratio has never been calculated for gender-affirming treatment. We stress the need for cost-effectiveness analyses in the field of trans health, as those types of studies can highlight interventions that are relatively inexpensive yet have the potential to reduce gender dysphoria burden substantially.

**Breast development**
TW often consider breast development a key feature of feminization and it occurs predominantly during the first 6 months of GAHT, with maximum effect expected by 2–3 years. However, breast growth is often modest in TW. De Blok and colleagues reported increasing breast-to-chest circumference difference and a bra cup size of less than an AAA cup in 48.8% of TW after 1 year of GAHT, with only 3.6% gaining a bra cup size larger than an A cup, independent of age, weight change, smoking, body mass index (BMI), serum oestradiol levels and oestrogen administration route. Assessing breast development only with Tanner staging and not measurements, Fisher and colleagues showed breast development to Tanner 3 after 2 years of GAHT, with a shift from predominantly Tanner 2 after 6 months of GAHT to predominantly Tanner 3 after 12 months and almost all with Tanner ≥3 after 24 months. Additionally, anatomical differences in the thoracic bone structure compared with cis women may result in breast size appearing smaller than the objectively measured volume.

The impact of various combinations of different oestrogens, anti-androgens and progestogens on breast development was previously reviewed by Wierckx and colleagues, who concluded that current evidence did not support or refute any enhancement of breast development with progestogens. Pubertal data in people assigned female at birth (AFAB) (e.g. girls with Turner syndrome) argue for delaying progesterone as it causes ductal differentiation and may interfere with optimal breast development. Due to unsatisfactory effects of GAHT alone on breast growth and development, 60–70% of all TW sought additional surgical breast augmentation. Articles on breast development in TW report inconclusive results, possibly due to differences in methodology and the lack of prospective RCTs. Prior recently published on the potential benefits of progesterone use on breast development (among other conclusions) in TW but the perspective was limited to clinical experience, assumptions taken from in vitro and animal data, and selected data from cis women. It would be worthwhile for future studies to use volume measurements for examining hormonally induced breast development in TW over a longer follow-up period in a large cohort, which may result in the identification of predictive markers for breast development. Additionally, rigorous prospective RCTs of oestrogen and oestrogen plus progesterone may provide more conclusive data to guide routine use of progesterone for breast development.

**Bone health**
Oestrogen serves as a key regulator of bone health, and oestrogen deficiency is thought to play an important role in both the rapid decline in bone mineral density (BMD) seen in postmenopausal women as well as the more gradual loss seen with aging in men. However, questions remain as to the overall prevalence of low BMD and fracture in TW and the timing and dosing of oestrogen to optimize bone outcomes.

Studies have shown a high prevalence of low bone mass in TW when compared with cis men both prior to and while on GAHT. The two studies that looked at baseline peripheral quantitative computed tomography (pQCT) found that TW had lower areal BMD (aBMD), smaller cortical bone area and a thinner radial cortex compared with cis men. Additionally, these studies showed lower grip strength and muscle mass. Genetics is thought to play a large role in attainment of peak bone mass, but dietary composition,
exercise, puberty timing and lifestyle factors, such as smoking and alcohol use, are also influential. Some studies have shown low rates of physical activity and vitamin D in TW prior to GAHT.75 There has also been a question as to the role of gonadotropins in bone health as FSH was slightly higher in TW at baseline in one study.74 Some authors have argued that FSH may have effects on the bone, independently of oestradiol, although this is disputed.76,77 Early studies of TW treated with oestrogen also postulated a correlation between higher LH levels and lower BMD after GAS,78 although more recent studies have not confirmed this.79,80

With the initiation of oestrogen, most studies report a positive change in BMD in TW81,82 and some have shown associations with oestradiol level attained.80 A recent meta-analysis83 reviewed 13 studies with 392 TW and showed significant gains overall in lumbar spine (LS) BMD at 12 months [0.04 g/cm²; 95% confidence interval (CI) 0.03–0.060 g/cm²] and 24 months (0.06 g/cm²; 95% CI 0.04–0.08 g/cm²) which is the range often considered clinically significant. Changes at the hip were not significant in this group.

Body composition changes occur with GAHT and probably influence bone health. One review reported GAHT increases body weight 1–3 kg per year in TW in the setting of decreased lean mass and increased fat mass.83 A study of 142 TW in Brazil, many of whom were already on GAHT (86%) or underwent GAS (33%), assessed appendicular lean mass, as an approximation of muscle mass, derived by dual-energy X-ray absorptiometry (DXA) measurements. Appendicular lean mass was similar in cis women to TW but lower than in cis men at the baseline measurement. There was a positive correlation between appendicular lean mass and total fat mass that correlated with L1–L4 BMD and explained 14.9% of BMD variation.72 The question has been raised as to whether some of the improvement in DXA may be artefactual as it is affected by fat mass; however, the correlation between markers of bone turnover and BMD changes shown in some studies74 would dispute this.

An area of concern for bone health is treatment with GnRHas for puberty blockade in trans adolescents. From their use in other medical conditions such as prostate cancer, their deleterious effects on the bone are well known, although these have the potential to be reversible if treatments are stopped or add-back therapies can be given.84,85 In a study of 15 young adult TW, similarly to older adults, baseline BMDs were lower than the population mean at baseline.86 With GnRHas, BMD went down as expected; however, after initiation of GAHT, despite an increase in absolute aBMD, the Z-score at age 22 years was lower than at the start of treatment, with six people (40%) having an LS Z-score of <−2.0.86 Similar findings were reported in a larger trial of 28 adolescents/young adults, with some overlapping study participants, where BMD Z-scores decreased during treatment with GnRHas then increased after initiation of GAHT, but remained below the population average and below baseline levels even after 24 months of GAHT.87 Another recent study looked at the use of CPA in 21 late pubertal trans girls (Tanner 4 with mean bone age at study start of 17.1 ± 1.28 years) as a potential way to avoid the negative bone effects of GnRHas.88 However, after 1 year of therapy there was a loss of lean mass and gain of fat mass as well as a decrease in Z-scores most profoundly at the LS, but also at the femoral neck and total hip. These findings all raise concerns, particularly since youth today are starting GnRHas earlier than in these studies (i.e. they may be taking a GnRHa for a longer duration), which may have more significant deleterious effects on skeletal development and will require further study.

In summary, bone density in TW may run low even prior to initiation of GAHT. Lifestyle factors probably contribute to this. When GAHT is initiated, there are positive changes in BMD as well as some measures of bone quality, however the effect on fracture rates is not fully known as studies have not been powered to examine this end point. Questions remain as to the effect of type and route of oestrogen utilized as well as the effect of GnRHas, gonadectomy and anti-androgens on bone health. The US population, which may have differences in ethnicity, average BMI, lifestyle habits, types of oestrogens and anti-androgens used, and rates of gonadectomy compared with European cohorts, has not been well studied and certain measures bear repeating. As far as clinical recommendations for patients, the Endocrine Society guidelines18 suggest checking bone density in patients who have traditional risk factors for osteoporosis and specifically in those who stop hormones after gonadectomy. However, given
the high prevalence of low BMD even prior to the initiation of GAHT or GAS in TW, it may be reasonable to assess a baseline DXA earlier.

**Part 3: risks associated with GAHT**

**Cardiovascular morbidity and mortality**

There have been systematic reviews,\(^89-92\) meta-analyses,\(^89,93\) and narrative reviews\(^28,94\) on CV morbidity and mortality in TW. Based on available evidence, no consistent increased risk for CV mortality and morbidity is observed when adhering to the current GAHT regimens, although studies assessing CV outcomes in TW are generally limited by the lack of RCTs, relatively short follow up, not controlling for traditional CVD risk factors and the reported use of ethinyl oestradiol instead of the currently preferred bioidentical oestradiols.\(^31-33,91,95-103\)

Gooren and colleagues\(^104\) published on the apparent reversal of the traditional sex differences in CVD patterns. In contrast with cis women having a lower incidence of heart disease compared with cis men (up to age 75 years), TW treated with estrogens (plus anti-androgens) showed more CV pathology than trans men, individuals AFAB who have male gender identity, receiving testosterone. Aging and pre-existing CVD contributed to increased risk as well as ethinyl oestradiol (in doses 2–4 times of OCPs).\(^104\) Elamin and colleagues\(^89\) reported very few CV events [death, cerebrovascular accident (CVA), myocardial infarction (MI), venous thromboembolism (VTE)] in their 2010 review.

The longest follow up study (mean 19.4 ± 7.7 years) of GAHT in TW (mean age at hormone start 31.4 ± 11.4 years) was the Amsterdam cohort, reported by Asscheman and colleagues,\(^31\) which revealed very few CV events (18 and 5 observed cases of mortality by ischemic heart disease and CVA, respectively, out of 1,331 TW). There was an increased risk of mortality by ischemic heart disease among TW compared with the general population [standardized mortality ratio (SMR) 1.64; 95% CI 1.43–1.87] but not an increased risk of CVA (SMR 1.2; 95% CI 0.93–1.64), and the ischemic heart disease risk was driven by continuous ethinyl oestradiol use.\(^31\) In a study by Wierckx and colleagues,\(^32\) TW experienced more MI than cis men but a similar proportion compared with cis men. Cerebrovascular disease was higher in TW than in cis men and there was more type 2 diabetes mellitus in TW than controls.\(^32\)

The data are more conclusive about the increased risk of VTE in TW. Wierckx and colleagues\(^32\) found that 5% of TW had a VTE during GAHT (\(n=5\) in first year hormones, \(n=3\) during GAS). Getahun and colleagues\(^105\) reported on acute CV events as part of the Study of Transition, Outcomes and Gender (STRONG) cohort, consisting of 6,456 Kaiser Permanente members \([n=2842\\text{transfeminine (sic)}]\), and found a higher incidence of VTE among transfeminine participants compared with reference men [adjusted hazard ratio (aHR) 1.9; 95% CI 1.4–2.7] and reference women (aHR 2.0; 95% CI 1.4–2.8), though the absolute rates were still very low and the increased risk was driven by those with longer (>2 years) follow up. Transfeminine participants had a higher incidence of VTE, with 2- and 8-year risk differences of 4.1 (95% CI, 1.6–6.7) and 16.7 (95% CI, 6.4–27.5) per 1,000 persons relative to reference men and 3.4 (95% CI, 1.1–5.6) and 13.7 (95% CI, 4.1–22.7) relative to reference women, respectively. Another caveat with the STRONG cohort data is that the authors did not adjust for duration, type (including ethinyl oestradiol) or route of administration of GAHT.

Cigarette smoking is an independent risk factor for CVD and stroke\(^106\) as well as VTE.\(^107-110\) There are varying published rates of current smoking status among TW, including 15% in the STRONG study\(^101\) and 38.6% in the Amsterdam cohort.\(^31\) Wierckx and colleagues\(^32\) reported that 7 of 11 cases of VTE, 3 of 3 cases of MI, and 4 of 5 cases of transient ischemic attack/stroke were current or former smokers. Although not considered an absolute requirement to start GAHT, smoking cessation should be encouraged at every visit for CVD and overall health benefits. Myers and Safer\(^111\) reported a higher rate of smoking cessation among TW (64%) when they were strongly advised to quit before initiating GAHT compared with national smoking cessation rates (6.2%).

There has been a surge in reviews attempting to reassess CVD risk of GAHT, often reviewing the same mostly European studies on mortality and long-term safety in TW.\(^28,93,94,104,112\) More recently, data from the US have been published. Nokoff and colleagues\(^99\) analyzed responses to the 2015 Behavioral Risk Factor Surveillance Survey.
(BRFSS) in the US and found that TW had higher odds of reporting MI than cis women (OR 2.9; 95% CI, 1.5–5.3) but not cis men. Getahun and colleagues also reported the risk of ischemic stroke was higher among TW compared with cis women (aHR 1.9; 95% CI 1.3–2.6), again related to longer (>6 years) follow up, and the risk of MI was higher among TW overall compared with cis women but not higher among TW who initiated oestrogen during the enrolment period.

In addition, there is currently no evidence of increased risk for arterial hypertension and dyslipidaemia in TW, despite indicators of a possible increased cardiometabolic risk (e.g. increasing BMI, percent visceral fat and insulin resistance). In contrast, other markers suggest a decreased risk compared with reference men and women as well as trans men [e.g. less insulin resistance, decreasing/stable blood pressure, decreasing LDL and smaller waist-to-hip ratio (WHR)]. Some conflicting results can be explained by the older mean age of TW compared with trans men, geographical location, GAHT regimen, minority stress (e.g. feelings of discrimination) and lifestyle factors.

Studies on the effect of GAHT on weight among TW have revealed no change or increase in weight; however, there has been consistency in body composition findings of decreased lean mass and increased fat mass. Klaver and colleagues reported that body composition changes were similar between oral and transdermal oestradiol after adjustment for baseline BMI and age. There were higher odds of obesity among all trans US Veterans compared with ‘non-transgender’ US Veterans (aOR 1.58; 95% CI 1.48–1.70), lower rates of obesity among TW (23%) compared with cis women (27%) and cis men (28%) in the STRONG cohort, and higher odds of self-identified obesity among TW compared with cis women (OR 1.77; 95% CI 1.11–2.82) but not cis men (OR 0.93; 95% CI 0.58–1.48) in the 2015 BRFSS.

Given the lack of RCTs explaining the conflicting CV morbidity results among the available literature and the scarcity of data on older trans people, the importance of ongoing large-scale prospective studies, such as STRONG, the European Network for the Investigation of Gender Incongruence (ENIGI) and GEnder Dysphoria Treatment in Sweden (GETS), and optimal management of conventional risk factors (e.g. weight, LDL cholesterol, blood pressure, smoking) cannot be overemphasized. The absolute CV risk calculation should be performed according to local guidelines for the general population, prior to the initiation of GAHT as well as during follow up. As reference ranges for trans people are not yet defined, CV risk calculation using ‘male’ provides a sensitive estimate for TW but may lack specificity.

If CV risk factors are present, they should be managed according to the established population-based guidelines. In addition, as psychological stress can be as detrimental to CV health as physical stress, we recommend addressing psychological wellbeing. Table 3 summarizes CVD risk factors in TW.

Infertility
Due to the potential risk of infertility in TW taking oestradiol, it is imperative to discuss fertility preservation prior to the initiation of GAHT and throughout the transition process. Previous studies assessing testis biopsies in TW who underwent orchiectomy report conflicting results on the
presence of spermatogenesis, mainly due to diverse methodologies. Leavy and colleagues,\textsuperscript{141} reported severely impaired spermatogenesis in TW treated with oestrogens. Jindarak and colleagues\textsuperscript{142} described maturation arrest in 36.4%, hypospermatogenesis in 26%, Sertoli cell-only syndrome in 20.2%, normal spermatogenesis in 11%, and seminiferous tubule hyalinization in 6.4% of the specimens, although, only 10.4% had been using anti-androgens in addition to oestrogens and data about GAHT was missing in 39.0%. Schneider and colleagues\textsuperscript{143} reported normal testicular function in 48% of TW undergoing gonadectomy after stopping GAHT 2 or 6 weeks before gonadectomy or not stopping at all. However, only 71% were taking anti-androgens and no information was given about the duration or effectiveness of anti-androgen therapy before gonadectomy. As studies assessing the effects of GAHT on fertility in TW are currently inconclusive, the WPATH SOC, version 7,\textsuperscript{19} encourages healthcare professionals to discuss reproductive options before initiating treatment that may reduce fertility.

Orchiectomy leads to irreversible loss of natural reproductive capacity. Trans people generally access reproductive medicine for two reasons: for fertility preservation prior to/during the transition process and for fulfilling the parental desire. Even after orchiectomy, it remains possible to have genetically related children if gametes have been preserved beforehand. Fertility options in trans people are discussed in full detail by De Roo and colleagues.\textsuperscript{144}

Fertility preservation utilization rates are considered low in trans people (9.6–15% in adults, 2.8% in adolescents),\textsuperscript{145–148} although reported parental desire rates in TW range from 28.8% to 58%,\textsuperscript{145,149,150} which is often higher before transition.\textsuperscript{150} Although there are many options for fertility preservation in trans people,\textsuperscript{151} many trans people still consider fertility the price to pay for transition\textsuperscript{152} and cost remains an incredible barrier to undergoing fertility preservation.\textsuperscript{153} For TW who underwent pubertal suppression, fertility preservation was often not possible at pubertal developmental Tanner 2 stage.\textsuperscript{147} Adolescents are offered the choice of postponing pubertal suppression in order to proceed with fertility preservation or to initiate pubertal suppression at Tanner 2 and to interrupt the therapy for fertility preservation prior to initiation of GAHT. Therefore, it is

| Variable | Effect |
|----------|--------|
| Weight and body composition | Body mass index |
| | -/↑ |
| | Visceral fat |
| | ↑ |
| | Total body fat |
| | -/↑ |
| | Waist-to-hip ratio |
| | ↓/- |
| Blood pressure | Systolic blood pressure |
| | ↓/-/↑ |
| | Diastolic blood pressure |
| | ↓/-/↑ |
| Lipids | Total cholesterol |
| | ↓/-/↑ |
| | Low-density lipoprotein cholesterol |
| | ↓/-/↑ |
| | High-density lipoprotein cholesterol |
| | ↓/-/↑ |
| | Triglycerides |
| | ↓/-/↑ |
| Insulin resistance | Fasting glucose |
| | - |
| | Fasting insulin |
| | -/↑ |
| | Insulin sensitivity |
| | ↓↑ |

Note: Adapted from Defreyne and colleagues,\textsuperscript{92} Irwig\textsuperscript{94} and Gooren and colleagues.\textsuperscript{104}
important for healthcare providers to enquire about the fertility needs of trans people and to discuss reproductive options in each stage of the gender-affirming process. Future research should further evaluate the effects of oestradiol in the presence and absence of different types of anti-androgens on fertility in TW and better characterize the cost-effectiveness and live birth rates of different fertility preservation options for TW.

Part 4: other health considerations for TW

HIV/AIDS

HIV prevalence rates for TW have varied widely across studies likely due to limited sampling with a focus on TW who engage in sex work and heterogeneous data collection methods. For example, Becasen and colleagues recently published a meta-analysis of 88 US-based trans studies revealing that, among TW, laboratory-confirmed HIV prevalence was 14.1% (95% CI 8.7–22.2) and self-reported HIV infection was 21.0% (95% CI 15.9–27.2). A systematic review by Herbst and colleagues, published 10 years earlier, reported higher prevalence of TW testing positive for HIV infection (27.7%; 95% CI 24.8–30.6) and lower self-reported HIV (11.8%; 95% CI 10.5–13.2). These estimates, regardless of publication year, are much higher than the estimated HIV prevalence in the general US population (<0.5%). Baral and colleagues published an earlier systematic review and meta-analysis of studies from the US, Asia-Pacific, Latin America and Europe, finding a pooled HIV prevalence of 19.1% (95% CI 17.4–20.7), with higher prevalence associated with higher-income countries.

High-risk sexual behaviour, a risk factor for HIV infection, appears to be common among TW. Inconsistent condom use with primary as well as nonprimary and commercial partners, unprotected sex in sero-discordant relationships (i.e. one partner is HIV-positive) and sex while using substances of abuse are frequently reported. Engagement in sex work, another independent increased risk factor for HIV, is estimated to be high among TW. The disparities in housing, employment and access to healthcare and social services that many TW face may lead to economic marginalization and the feeling of needing to engage in sex work. HIV prevalence is also estimated to be higher for TW of colour, which may be partially explained by more TW of colour being involved in sex work and facing double stigmatization for their race/ethnicity and gender identity.

The higher rates of HIV in TW are also related to increased morbidity and mortality. Asscheman and colleagues reported that the higher risk of mortality among TW compared with the general population was mainly due to AIDS (SMR 30.20; 95% CI 26.0–34.7). HIV prevention, treatment and care utilization should be priorities around the world, but TW experience many barriers to treatment even after receiving an HIV diagnosis. There have been concerns about hormone–drug interactions between GAHT and medications used to prevent and treat HIV. Radix and colleagues reviewed the literature on antiretroviral therapy (ART) use among TW and found that most studies have addressed interactions between ethinyl oestradiol (no longer recommended for GAHT as described above) and non-nucleoside reverse transcriptase inhibitors and protease inhibitors. Preexposure prophylaxis (PrEP), consisting of a tenofovir disoproxil fumarate/emtricitabine combination pill, is effective in preventing HIV infection though uptake in use has been limited. There are calls for increased PrEP utilization in TW when clinically indicated. Research efforts in this area should continue to focus on TW’s unique barriers to optimal HIV screening, prevention and treatment as well as potential interactions between guideline-recommended oestradiol formulations/routes of administration and ART.

Breast cancer

The long-term use of oestrogen in TW enables them to develop and maintain breasts but also raises concern about the development of cancer in the breast and other oestrogen-sensitive tissues. Retrospective cohort studies have demonstrated no cases or few cases of breast cancer but similar incidences to the general population, depending on study period, follow up and whether rates were compared with cis women or cis men. Rates from a large Dutch TW cohort between 1975 and 2011 (n = 2,307 and 52,370 person-years of GAHT exposure) found 4.1 cases per 100,000 person-years (95% CI 0.8–13.0) which was lower than expected if the one confirmed and second suspected cases were regarded as female breast cancer (170 per 100,000 person-years), but similar to that
expected if regarded as male breast cancer (1.2 per 100,000 person-years). A more recent retrospective analysis of the Dutch TW cohort between 1972 and 2016, but with fewer TW included, showed an increased risk of breast cancer in TW compared with Dutch cis men [standardized incidence ratio (SIR) 46.7, 95% CI 27.2–75.4] but a decreased risk compared with Dutch cis women (SIR 0.3, 95% CI 0.2–0.4). The cases occurred at a younger age and after short exposure to oestrogen ± progestins. In the US, Brown and Jones reported a higher incidence of breast cancer among TW and trans men veterans compared with published European cohorts, but a similar rate to an age-standardized US national sample.

As there is currently no evidence that breast cancer risk among TW is higher compared with cis women, we recommend following local population guidelines for breast cancer screening in women. Other recommendations for breast cancer screening in TW on continuous GAHT have included annual mammogram in those aged >50 years with additional risk factors such as having used oestrogen ± progestin for >5 years, a BMI >35 kg/m² or a family history of breast cancer. A recent review by Sonnenblick and colleagues provided radiologists with recommendations for culturally sensitive care for TW (and trans men) with regard to screening and diagnostic breast imaging as well as noted histologic and imaging changes due to GAHT. Noted caveats to breast cancer screening in TW include lack of evidence for these recommendations and how to manage TW with breast implants. Mammography becomes less sensitive in the presence of implants, therefore it is imperative to remind TW with implants to provide complete implant histories to the ordering providers and imaging technologists. Although mammography with additional views is still suggested for routine breast cancer screening in patients with breast implants regardless of gender identity, ultrasound is recommended as first-line imaging to investigate implant complications in those with pain, lumps or asymmetries. Magnetic resonance imaging (MRI) can be performed after ultrasound especially if there is concern about intracapsular rupture not visible by ultrasound. Others recommend comprehensive and individually tailored screening programs for trans people (e.g. possible gradual reduction of exogenous oestradiol doses with age and stimulating menopause in TW). Additional prospective research is needed to better characterize predictors of breast cancer in TW as well as if there is different cost-effectiveness among screening modalities based on gender identity.

**Other tumours**

The long-term follow-up study of mortality that included 966 TW in the Netherlands who started GAHT prior to 1 July 1997, and with at least 1 year of follow up, did not find an increase in overall mortality from malignant neoplasm in TW (SMR 0.9; 95% CI 0.88–1.08). However, among the reported deaths from a malignant neoplasm, there was a higher SMR for lung (1.35; 95% CI 1.14–1.58) and haematological (2.58; 95% CI 1.97–3.30) malignancies but lower SMR for digestive tract (0.42; 95% CI 0.28–0.60) malignancies compared with the general population. GAS for TW generally does not include prostatectomy and questions arise about prostate cancer screening in TW. Prostate ultrasonography and biopsy demonstrated atrophy in nine TW aged 51–71 years with a mean of 15.8 years after oestrogen initiation and 13.4 years after orchiectomy, with few androgen receptors but ample oestrogen and progesterone receptors in stroma and epithelium. Gooren and Morgentaler reported one case of prostate cancer in a 63 year-old TW [among 2,307 TW (incidence rate 0.04%) who had a mean follow up of 21.4 ± 8.7 years] who had initiated GAHT at age 53 years and underwent orchiectomy at age 55 years. Additional cases of prostate cancer have been reported more recently. A total of 11 case reports have been published in TW with age at diagnosis between 54 and 78 years, the majority being metastatic on presentation (none of the 3 cases published after 2016), and years on GAHT between 6 and 41 years. There is no consensus on routine prostate cancer screening among TW, with a caveat that prostate-specific antigen (PSA) cut-offs in TW are unknown. PSA should be low or undetectable in the setting of suppressed serum testosterone due to feminizing GAHT or orchiectomy, but we also do not have data to determine PSA utility in TW who are unable to achieve suppressed serum testosterone levels before orchiectomy. Following individualized population guidelines for screening in cis men may be appropriate for TW with prostate tissue...
present as suggested in the Endocrine Society guidelines.\textsuperscript{18}

There have also been some studies on brain tumours in TW. Meningiomas, benign tumours that are twice as likely in cis women compared with cis men and thought to be hormonally sensitive, were reported in 3 of 2,810 TW in the Amsterdam cohort treated between 1975 and 2011.\textsuperscript{193} In reviews of the literature, CPA dosage was high, mostly 100 mg/day (but as low as 10 mg/day) and time from CPA start to meningioma diagnosis ranged from 1 to 25 years.\textsuperscript{193,194} Prolactinoma in TW has also been reviewed and associated with high-dose CPA.\textsuperscript{189} While the recent Endocrine Society guidelines\textsuperscript{18} suggest periodic monitoring of serum prolactin, a downgraded recommendation from the previous rendition, future studies will help us determine whether routine prolactin screening is needed particularly in TW who do not take CPA. Defreyne and colleagues\textsuperscript{195} revealed that CPA increased prolactin levels in TW but the levels decreased when TW discontinued CPA. Fung and colleagues\textsuperscript{117} demonstrated higher prolactin levels in TW receiving CPA than those taking spironolactone. Given these newer data, we recommend checking prolactin only in those patients with signs or symptoms of hyperprolactinaemia before or after starting feminizing GAHT.

Other reproductive cancers in TW have been reviewed and include neovaginal and testicular.\textsuperscript{192} There was also a case report of an oestrogen receptor beta-positive mature testicular teratoma in a TW taking oestradiol and progesterone.\textsuperscript{196} There is still no consensus on the screening of these type of tumours, probably given their rare occurrences, and ongoing long-term studies will shed more light on whether or not routine screening for these tumours is needed in TW.

**Voice therapy**

In TW who went through puberty according to their sex assigned at birth, exposure to androgens has resulted in acoustic changes, which become noticeable from a testosterone concentration of 150 ng/dl and higher. Repeated exposure to concentrations higher than 200 ng/dl results in irreversible changes.\textsuperscript{197} Certain characteristics of voice and speaking are more frequently perceived as male or female, such as frequency ranges [male (<145 Hz), overlap (145–165 Hz) and female (>165 Hz) range],\textsuperscript{198,199} resonance (which is typically higher in voices perceived as female), inflections (more frequent and upward gliding perceived as a feminine characteristic of voice), articulation (more articulation perceived as a feminine characteristic of voice), speaking intensity (speaking more quietly is perceived as a feminine characteristic of voice) and breathiness (perceived as a feminine characteristic of voice).\textsuperscript{200}

Patient-reported outcomes have shown an improvement in TW’s voice-related gender identity perception, voice-related anxiety, avoidance of situations due to their voice and voice quality during the first year of GAHT, even in TW who did not undergo voice therapy or voice surgery.\textsuperscript{197} However, these improvements were unrelated to prospective changes in serum testosterone levels and influences other than the GAHT (e.g. more gender-congruent feelings because of breast development) may play a role in the improving self-perception of voice occurring in TW.

Still, many TW reported voice-related problems in everyday life, especially when communicating over the telephone, when they sense irritation and hesitation in their conversation partners or when addressed as male.\textsuperscript{201–203} Aiming for a more feminine voice, TW sometimes perform vocal compensations, such as elevation of the larynx in speech, which may result in vocal hyperfunction and a higher occurrence of vocal complaints.\textsuperscript{204} Being perceived as male is negatively correlated to personal satisfaction of the voice, even if the fundamental frequency is within the female range.\textsuperscript{205} However, Hancock and colleagues,\textsuperscript{206} reported that QOL ratings in TW are strongly correlated with their self-rated perception of voice and only moderately related to how others perceive their voice.

The goal of speech-language therapists and pathologists is to help TW develop voice and communication that reflects their gender identity without causing laryngeal injury, a goal that is beyond achieving fundamental frequency within the female range,\textsuperscript{200} which is often the goal of phonosurgery.\textsuperscript{207} Ultimately, the patient’s goals and perceptions are most important\textsuperscript{207} and an individualized approach is preferred. Additional research can help us identify predictors of attaining the desired voice pitch among TW and which vocal therapy techniques achieve the best patient-reported outcomes.
**Dermatologic considerations**

There have been several reviews of dermatologic and hair disorders in trans populations. There have been several reviews of dermatologic and hair disorders in trans populations. Among TW taking GAHT, oestrogens slow down male pattern hair growth, decrease sebum production and possibly improve acne but can also increase xerosis and brittle nails. The onset of skin softening and decreased oiliness starts in 3-6 months but the time to maximum effects is unknown. Meanwhile, decreased terminal hair growth begins at 6-12 months with maximum effect at >3 years. GAS may require preoperative hair removal to facilitate better postoperative outcomes and reduce the risk of scarring or developing hair in undesired areas. TW who underwent suppression with GnRHAs would not have had development of androgen-dependent hair nor need laser/electrolysis treatments for hair removal. In those already with or at high risk of contracting HIV or other sexually transmitted infections, skin manifestations related to those infections may arise. There was also a report of squamous cell carcinoma arising from the penile skin in a neovagina 20 years after a trans woman underwent GAS.

Another dermatologic consideration is the use of silicone. In a Belgian cohort of sex workers, 65% reported having silicone injections in one or more parts of the body (buttocks, legs, face, hips, breasts), frequently injected by a friend without medical training (53%). The use of silicone injections among TW has led to reports of Mycobacterium abscessus cellulitis and abscesses of the breasts, granuloma formation and hypercalcemia and lymphoedema from migrating silicone. Injecting silicones can have major complications that can arise any time after the injections took place, and as such should be discouraged according to healthcare specialists.

Facial hair growth may persist despite the use of oestrogens and anti-androgens; therefore, TW may resort to various cosmetic procedures including shaving, waxing, plucking, electrolysis, and laser or intense pulsed light hair removal, though no studies have been done comparing the efficacy of different methods nor the timing of the procedures with hormone initiation. Efornithine cream has been used for facial hair removal in cis women but not studied in TW, though effects are not permanent and may be a less desirable option. More studies are needed to determine the most effective cosmetic procedures to facilitate unwanted hair removal, to identify predictors of achieving desired feminizing skin features, and how to better provide TW with access to these cosmetic procedures.

**The brain and cognition**

Recent studies have investigated baseline differences between the brains of trans versus cis individuals as well as the effect of GAHT on the brain and cognition. The white matter microstructure of TW prior to initiation of GAHT has been characterized by diffusion tensor imaging to be between control females and control males. Hahn and colleagues also described different structural connectivity networks in 21 TW prior to initiating GAHT compared with control females and males. Seiger and colleagues analyzed brain MRIs of 14 TW (mean age 26.9 ± 6.1 years) at baseline and after at least 4 months (169 days ± SD 38 days) of continuous oral or transdermal oestradiol and anti-androgens (cyproterone acetate ± GnRHa ± finasteride) and found decreases in the hippocampal region, increases in the ventricles and a correlation between progesterone levels and changes in grey matter structure. Mueller and colleagues found neuroanatomical volume differences in the amygdala, putamen and corpus callosum in TW compared with cis women but not cis men, suggesting the possibility of localized influence of sex hormones on neuroanatomy. These studies suggest there are hormonal influences on cortical and subcortical structures related to cognition, memory and emotional processing. Reviews stress that additional short- and long-term studies are needed to better understand the role of sex hormones on the adult human brain structure and function and how they relate to psychological differences between females and males.

Brain-derived neurotrophic factor (BDNF) is involved in neurogenesis, neuronal maturation and synaptogenesis, influencing brain plasticity. A study of 10 TW from Belgium showed a significant decrease in BDNF levels after 12 months of GAHT (p = 0.014) independent of age, weight, BMI, total fat mass, total lean mass, LH, FSH, oestradiol, testosterone, cortisol, physical activity or smoking. Therefore, it was concluded that the decreased BDNF in TW after GAHT resulted from the GAHT rather than as a consequence of or risk factor for gender identity.
Nguyen and colleagues\textsuperscript{232} published a recent review of cross-sectional and longitudinal studies from the last 5 years, nearly all from European cohorts, and summarized fewer depressive symptoms, anxiety, problems with socialization and interpersonal functioning, global functional impairment, interpersonal sensitivity and hostility in TW on GAHT compared with baseline. They also summarized the general findings above that GAHT is correlated with changes in global and regional brain volumes, white matter microstructure and in cognitive performance on sex-biased tasks requiring verbal and visual memory in the direction of gender identity rather than assigned sex.\textsuperscript{232} However, no studies have examined how GAHT influences executive function and cognitive domains used for daily living, and additional research will provide valuable data on these and other brain processes.

\textbf{Aging}

Regarding older TW (arbitrarily defined as aged >50 years), very little data exist on the short- and long-term effects and safety of GAHT.\textsuperscript{1,2,23,30,233} Aging-related questions yet to be answered include: (1) Do older TW on chronic oestrogen therapy (± anti-androgens) have similar biological–endocrinological status as age-matched cis women?; (2) Which doses and modes of administration are the safest in older age?; (3) Is there an age at which GAHT initiation is not safe to initiate?; and (4) For how long should hormones be continued in the elderly? Answers to these questions will help us address both chronic effects as well as older age-specific effects from GAHT.

Despite the valuable data on the risks of VTE, CV events and breast cancer with conjugated equine oestrogens ± medroxyprogesterone acetate in postmenopausal women aged 50–79 years during the Women’s Health Initiative (WHI) in the US,\textsuperscript{234–235} extrapolating these data from WHI to TW cannot be done completely due to sex chromosomes, anatomic and physiological differences, and the administration of oestrogens ± progestins not routinely used in GAHT for TW. More research is needed in this area of short- and long-term safety of oestradiol formulations in older TW, particularly with dosing, goal hormone levels, routes of administration and duration of treatment.

The US Veterans Health Administration (VHA) has been and will be a significant source of data among older trans people;\textsuperscript{238–240} however, published retrospective studies on mortality and other medical and mental health disparities among VHA veterans have mostly looked at the general trans veteran population (rather than TW specifically) and did not take into account presence or type of GAHT nor gonadectomy status. Nonetheless, important data include: (1) similar top 10 causes of death among trans VHA veterans (mean age of death 64.2 years; range 25.0–91.0) and the US population at the time (with diseases of the circulatory system and neoplasm being the top 2);\textsuperscript{241} (2) higher crude suicide rates among the trans cohort compared with the general VHA and US populations and occurred at a younger mean age (49.4 years; range 25.0–73.0) than the general VHA population;\textsuperscript{241} and (3) higher odds of 10 mental health diagnoses and 14 of 17 medical diagnoses, including HIV and multiple CV risk factors, among the trans veterans compared with the cis veterans.\textsuperscript{134}

Other trans cohorts with promising proportions of older TW to allow for additional assessments of age-related comorbidities and associations with GAHT include the Amsterdam Gender Clinic, which reported 700 of 4,432 (15.8\%) TW reached the age of 60 years or above in 2015,\textsuperscript{30} and the STRONG study that will follow a transfeminine cohort of 3,475, of whom 16\% were aged 46–55 years and 14\% were aged >55 years at study enrollment.\textsuperscript{101} In contrast, the European Network for the investigation of Gender Incongruence (ENIGI) has often published results on a variety of topics discussed above in mostly younger cohorts, though the ENIGI Endocrine protocol, which began in 2010, had a wide range of ages in the TW cohort (median 30 years; range 16–65) that was described in 2015.\textsuperscript{138}

The TW population continues to age and there are increasing numbers of older TW in many of the cohorts described above. Older TW deserve as much thoughtful and sensitive care as younger TW and nontrans older adults. The intersection of aging and transgender health is a novel area of research that can focus on the impact of aging on TW health outcomes, individual goals and desires associated with aging, and end-of-life and palliative care issues.
Conclusion

Trans health is an evolving field that includes physiological, psychological and societal considerations for the optimization of health. In addition to the increasing presence of gender diversity in the mainstream media, the medical literature has benefited from more publications on the risks and benefits of GAHT on the lives of trans people. In this narrative review, we aimed to comprehensively summarize important health considerations specific to TW that are important to them and their providers. We included the consistent evidence that GAHT improves QOL and mental health, has modest effects on breast development and positively impacts bone health in TW. Careful interpretation of TW’s baseline characteristics and type of GAHT regimen is needed when evaluating studies showing increased relative (albeit still low absolute) risks of VTE and stroke in TW compared with cis women and men. Nonetheless, CVD risk factors (e.g. obesity, smoking, diabetes, hypertension, hyperlipidaemia) should be optimized if present. Infertility risk and fertility desire should ideally be addressed prior to the start of GAHT. TW appear to have higher risk of breast cancer compared with cis men but not cis women, so we recommend following local population guidelines for breast cancer screening in women. Although we could not address all aspects related to TW’s health, we included topics not often addressed or elaborated on in other reviews such as HIV/AIDS, other tumours, voice therapy, dermatologic considerations, the brain and cognition and aging.

Additionally, we identified areas of future research (Table 4) that will hopefully provide answers to persistent questions surrounding TW’s health. We strongly advocate for more RCTs and large prospective cohort studies in order to further build confidence that the benefits of feminizing GAHT outweigh the risks for TW. We anticipate rigorous data to continue to be shared from ENIGI, STRONG, GETS and any other cohorts that may be getting underway soon. We also eagerly await the new WPATH SOC, version 8, to provide its up-to-date global perspective of evidence-based recommendations for trans health, adding to a growing literature that is helping healthcare providers take care of their trans patients.

### Table 4. Suggested areas of research still needed to address health considerations for TW.

| Topic                                    | Areas of research                                                                 |
|-------------------------------------------|-----------------------------------------------------------------------------------|
| Gender-affirming hormone therapy          | 1. Randomized controlled trials comparing oral, transdermal and parenteral oestradiol and the various anti-androgens |
|                                           | 2. Safety and efficacy of sublingual and pellet formulations of oestradiol        |
|                                           | 3. Predictors of feminization based on individual TW baseline characteristics     |
|                                           | 4. Long-term outcome studies in TW who underwent pubertal suppression with GnRHs |
|                                           | 5. Safety and efficacy of alternative anti-androgens (e.g. progesterone, finasteride/dutasteride, bicalutamide) |
|                                           | 6. Reducing barriers to access to GAHT among TW                                  |
|                                           | 7. More studies in gender nonbinary individuals AMAB who desire feminization to see how taking feminizing GAHT effects their health outcomes, which doses are most appropriate for nonbinary goals and whether or not these outcomes are similar to those in TW |
| Quality of life and mental health         | 1. Cost-effectiveness analyses highlighting feminizing interventions and their potential to reduce gender dysphoria burden substantially |
| Breast development                        | 1. Studies using long-term volume measurements for examining hormonally induced breast development in TW |
|                                           | 2. Identifying predictive markers for breast development                         |
|                                           | 3. Rigorous prospective RCTs of oestrogen and oestrogen plus progesterone for breast development |
| Bone health                               | 1. Overall prevalence of low BMD and fracture in TW                              |
|                                           | 2. Timing and dosing of oestrogen to optimize bone outcomes                       |
|                                           | 3. Studies on the long-term bone health effects of GnRHs and other anti-androgens as well as orchiectomy |
|                                           | 4. Determine whether DXA should be routinely be obtained prior to GAHT or GAS     |
|                                           | 5. Collecting bone health data in the US population which is has more diversity, older age at initiation of GAHT or GAS, lower tobacco smoking rates, higher overweight and obesity rates, and fewer gonadectomies |

(Continued)
Table 4. (Continued)

| Topic                        | Areas of research                                                                 |
|------------------------------|-----------------------------------------------------------------------------------|
| Cardiovascular disease morbidity and mortality | 1. Additional long-term data on CVD risk factors in more diverse TW populations  
2. Weight loss or obesity intervention studies among TW  
3. Data to support which sex-based CVD risk calculations should be made for TW |
| Infertility                  | 1. The effects of oestradiol in the presence and absence of different types of anti-androgens on fertility in TW  
2. Cost-effective analyses and comparison of live birth rates of different fertility preservation options |
| HIV/AIDS                    | 1. Identifying solutions to TW’s unique barriers to optimal HIV screening, prevention and treatment  
2. Better understanding of potential interactions between guideline-recommended oestradiol formulations/routes of administration and HIV medications |
| Breast cancer               | 1. Prospective research to better characterize predictors of breast cancer in TW  
2. Cost-effective analyses to determine the best breast cancer screening modalities based on gender identity, duration of GAHT and presence of implants |
| Other tumours               | 1. Determine PSA utility in screening for prostate cancer in TW who are unable to achieve suppressed serum testosterone levels before orchiectomy  
2. Ongoing long-term studies whether routine screening for other tumours is needed in TW (e.g. meningioma, prolactinoma) |
| Voice therapy               | 1. Identifying predictors of attaining the desired voice pitch among TW  
2. Determining which vocal therapy techniques achieve the best patient-reported outcomes |
| Dermatologic considerations | 1. Determining the most effective cosmetic procedures to facilitate unwanted hair removal  
2. Identifying predictors of how to achieve positive feminizing skin features  
3. How to better provide TW with access to cosmetic procedures |
| The brain and cognition     | 1. Studies on how GAHT influences executive function and cognitive domains used for daily living |
| Aging                       | 1. The impact of aging on TW health outcomes to help us answer:  
a. Do older TW on chronic oestrogen therapy (+ anti-androgens) have a similar biological–endocrinological status as age-matched cis women?  
b. Which doses and modes of administration are the safest in older age?  
c. Is there an age at which GAHT initiation is not safe to initiate?  
d. For how long should hormones be continued in the elderly?  
2. Understanding individual goals and desires associated with aging including end-of-life and palliative care issues |

AMAB, assigned male at birth; BMD, bone mineral density; CVD, cardiovascular disease; DXA, dual-energy X-ray absorptiometry; GAHT, gender-affirming hormone therapy; GAS, gender-affirming surgery; GnRH, gonadotropin-releasing hormone agonist; PSA, prostate-specific antigen; RCT, randomized controlled trial; TW, transgender women.

Acknowledgements
This collaboration was supported in part by an American Association of Clinical Endocrinologists and American College of Endocrinology (AACE/ACE) Lewis E. Braverman, MD, MACE, Education Fund (SJI; co-mentors: GT and MSR).

Author’s Note
SJI conceived of the review, participated in the design and coordination and drafted the manuscript. JD conceived of the review, participated in the design and drafted the manuscript. MSR participated in the design and drafted the manuscript. JVS drafted the manuscript. LVB drafted the manuscript. JM participated in the design and drafted the manuscript. All authors read and approved the final manuscript.

Funding
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This perspective review received no specific grant from...
any funding agency in the public, commercial, or not-for-profit sectors. SJI is supported by an Advanced Fellowship in Geriatrics from the Geriatric Research, Education, and Clinical Center, Rocky Mountain Regional VA Medical Center, VA Eastern Colorado Health Care System, Office of Academic Affiliations, US Department of Veterans Affairs.

**Conflict of interest statement**

GT has scientific grants as Principal Investigator from Ipsen, Bayer Shering and Sandoz. GT receives a consulting fee as an advisory board member for Ipsen and Novartis. GT receives a lecturer fee as a speaker for Ferring and Novartis. The remaining authors declare that they have no conflict of interest.

**ORCID iD**

Sean J. Iwamoto  [https://orcid.org/0000-0002-7316-8256](https://orcid.org/0000-0002-7316-8256)

**References**

1. Feldman J, Brown GR, Deutsch MB, et al. Priorities for transgender medical and healthcare research. *Curr Opin Endocrinol Diabetes Obes* 2016; 23: 180–187.
2. Reisner SL, Deutsch MB, Bhasin S, et al. Advancing methods for US transgender health research. *Curr Opin Endocrinol Diabetes Obes* 2016; 23: 198–207.
3. James SE, Herman JL, Rankin S, et al. The report of the 2015 U.S. transgender survey. Washington, D.C.: national Center for Transgender Equality, 2016.
4. *Being trans in the European Union: comparative analysis of EU LGBT survey data*. Luxembourg: European Union Agency for Fundamental Rights, 2014.
5. Davidge-Pitts CJ, Nippoldt TB and Natt N. Endocrinology fellows’ perception of their confidence and skill level in providing transgender healthcare. *Endocr Pract* 2018; 24: 1038–1042.
6. Irwig MS. Transgender care by endocrinologists in the United States. *Endocr Pract* 2016; 22: 832–836.
7. Shires DA, Stroumsa D, Jaffee KD, et al. Primary care clinicians’ willingness to care for transgender patients. *Ann Fam Med* 2018; 16: 555–558.
8. Defreyne J, Motmans J and T’Sjoen G. Healthcare costs and quality of life outcomes following gender affirming surgery in trans men: a review. *Expert Rev Pharmacoecon Outcomes Res* 2017; 17: 543–556.
9. Fisher AD, Castellini G, Bandini E, et al. Cross-sex hormonal treatment and body uneasiness in individuals with gender dysphoria. *J Sex Med* 2014; 11: 709–719.
10. Fisher AD, Castellini G, Ristori J, et al. Cross-sex hormone treatment and psychobiological changes in transsexual persons: two-year follow-up data. *J Clin Endocrinol Metab* 2016; 101: 4260–4269.
11. Gomez-Gil E, Zubi aure-Elorza L, Esteva I, et al. Hormone-treated transsexuals report less social distress, anxiety and depression. *Psychoneuroendocrinology* 2012; 37: 662–670.
12. Gorin-Lazard A, Baumstarck K, Boyer L, et al. Is hormonal therapy associated with better quality of life in transsexuals? A cross-sectional study. *J Sex Med* 2012; 9: 531–541.
13. Murad MH, Elamin MB, Garcia MZ, et al. Hormonal therapy and sex reassignment: a systematic review and meta-analysis of quality of life and psychosocial outcomes. *Clin Endocrinol (Oxf)* 2010; 72: 214–231.
14. Newfield E, Hart S, Dibble S, et al. Female-to-male transgender quality of life. *Qual Life Res* 2006; 15: 1447–1457.
15. Smith YL, Van Goozen SH, Kuiper AJ, et al. Sex reassignment: outcomes and predictors of treatment for adolescent and adult transsexuals. *Psychol Med* 2005; 35: 89–99.
16. Weyers S, Elaut E, De Sutter P, et al. Long-term assessment of the physical, mental, and sexual health among transsexual women. *J Sex Med* 2009; 6: 752–760.
17. Wierckx K, Elaut E, Van Hoorde B, et al. Sexual desire in trans persons: associations with sex reassignment treatment. *J Sex Med* 2014; 11: 107–118.
18. Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab* 2017; 102: 3869–3903.
19. Coleman E, Bockting W, Botzer M, et al. Standards of care for the health of transsexual, transgender, and gender-nonconforming people, version 7. *Int J Transgenderism* 2012; 13: 165–232.
20. UCSF Transgender Care, Department of Family and Community Medicine, University
of California San Francisco. Guidelines for the primary and gender-affirming care of transgender and gender nonbinary people, 2nd edition. Deutsch MB, ed. Available at transcare.ucsf.edu/guidelines (June 2016, accessed July 22, 2019).

21. Abramowitz J and Tangpricha V. Hormonal management for transfeminine individuals. *Clin Plast Surg* 2018; 45: 313–317.

22. Meriggiola MC and Gava G. Endocrine care of transpeople part II. A review of cross-sex hormonal treatments, outcomes and adverse effects in transwomen. *Clin Endocrinol (Oxf)* 2015; 83: 607–615.

23. Tangpricha V and den Heijer M. Oestrogen and anti-androgen therapy for transgender women. *Lancet Diabetes Endocrinol* 2017; 5: 291–300.

24. T’Sjoen G, Arcelus J, Gooren L, et al. Endocrinology of transgender medicine. *Endocr Rev*. Epub ahead of print October 2018. DOI: 10.1210/er.2018–00011.

25. Wesp LM and Deutsch MB. Hormonal and surgical treatment options for transgender women and transfeminine spectrum persons. *Psychiatr Clin North Am* 2017; 40: 99–111.

26. Cunha FS, Domenice S, Sircili MHP, et al. Low estrogen doses normalize testosterone and estradiol levels to the female range in transgender women. *Clinics (Sao Paulo)* 2018; 73: e86.

27. Liang JJ, Jolly D, Chan KJ, et al. Testosterone levels achieved by medically treated transgender women in a United States endocrinology clinic cohort. *Endocr Pract* 2018; 24: 135–142.

28. Streed CG Jr, Harfouch O, Marvel F, et al. Cardiovascular disease among transgender adults receiving hormone therapy: a narrative review. *Ann Intern Med* 2017; 167: 256–267.

29. Gooren L and Lips P. Conjectures concerning cross-sex hormone treatment of aging transsexual persons. *J Sex Med* 2014; 11: 2012–2019.

30. Gooren LJ and T’Sjoen G. Endocrine treatment of aging transgender people. *Rev Endocr Metab Disord* 2018; 19: 253–262.

31. Asscheman H, Giltay EJ, Megens JA, et al. A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. *Eur J Endocrinol* 2011; 164: 635–642.

32. Wierckx K, Elaut E, Declercq E, et al. Prevalence of cardiovascular disease and cancer during cross-sex hormone therapy in a large cohort of trans persons: a case-control study. *Eur J Endocrinol* 2013; 169: 471–478.

33. Wierckx K, Mueller S, Weyers S, et al. Long-term evaluation of cross-sex hormone treatment in transsexual persons. *J Sex Med* 2012; 9: 2641–2651.

34. Defreyne J, Vantomme B, Van Caenegem E, et al. Prospective evaluation of hematocrit in gender-affirming hormone treatment: results from European network for the investigation of gender incongruence. *Andrology* 2018; 6: 446–454.

35. Schagen SE, Cohen-Kettenis PT, Delemarre-van de, Waal HA, et al. Efficacy and safety of gonadotropin-releasing hormone agonist treatment to suppress puberty in gender dysphoric adolescents. *J Sex Med* 2016; 13: 1125–1132.

36. Cools M, Craen M and T’Sjoen G. The endocrine treatment of transsexual adolescents. *Tijdschr Geneeskd* 2010; 66: 28–33.

37. Gava G, Cerpolini S, Martelli V, et al. Cyproterone acetate vs leuprolide acetate in combination with transdermal oestradiol in transwomen: a comparison of safety and effectiveness. *Clin Endocrinol (Oxf)* 2016; 85: 239–246.

38. Leinung MC, Feustel PJ and Joseph J. Hormonal treatment of transgender women with oral estradiol. *Transgend Health* 2018; 3: 74–81.
hirsutism: a double-blind randomized controlled trial. *J Clin Endocrinol Metab* 2018; 103: 824–838.

44. Van Schuylenbergh J, Motmans J, Defreyne J, *et al.* Sexual health, transition-related risk behaviour and need for healthcare among transgender sex workers (in review). *Int J Transgend* 2019: 1–15.

45. Rotondi NK, Bauer GR, Scanlon K, *et al.* Nonprescribed hormone use and self-performed surgeries: “do-it-yourself” transitions in transgender communities in Ontario, Canada. *Am J Public Health* 2013; 103: 1830–1836.

46. Sanchez NF, Sanchez JP and Danoff A. Health care utilization, barriers to care, and hormone usage among male-to-female transgender persons in New York City. *Am J Public Health* 2009; 99: 713–719.

47. Mepham N, Bouman WP, Arcelus J, *et al.* People with gender dysphoria who self-prescribe cross-sex hormones: prevalence, sources, and side effects knowledge. *J Sex Med* 2014; 11: 2995–3001.

48. Nobili A, Glazebrook C and Arcelus J. Quality of life of treatment-seeking transgender adults: a systematic review and meta-analysis. *Rev Endocr Metab Disord* 2018; 19: 199–220.

49. Basar K, Oz G and Karakaya J. Perceived discrimination, social support, and quality of life in gender dysphoria. *J Sex Med* 2016; 13: 1133–1141.

50. Gomez-Gil E, Zubiaurre-Elorza L, de Antonio IE, *et al.* Determinants of quality of life in Spanish transsexuals attending a gender unit before genital sex reassignment surgery. *Qual Life Res* 2014; 23: 669–676.

51. Yang X, Zhao L, Wang L, *et al.* Quality of life of transgender women from China and associated factors: a cross-sectional study. *J Sex Med* 2016; 13: 977–987.

52. Heylens G, Verroken C, De Cock S, *et al.* Effects of different steps in gender reassignment therapy on psychopathology: a prospective study of persons with a gender identity disorder. *J Sex Med* 2014; 11: 119–126.

53. Colizzi M, Costa R and Todarello O. Transsexual patients’ psychiatric comorbidity and positive effect of cross-sex hormonal treatment on mental health: results from a longitudinal study. *Psychoneuroendocrinology* 2014; 39: 65–73.

54. Manieri C, Castellano E, Crespi C, *et al.* Medical treatment of subjects with gender identity disorder: the experience in an Italian public health center. *Int J Transgenderism* 2014; 15: 53–65.

55. Motmans J, Meier P, Ponnet K, *et al.* Female and male transgender quality of life: socioeconomic and medical differences. *J Sex Med* 2012; 9: 743–750.

56. Cohen-Kettenis PT and Gooren LJ. Transsexualism: a review of etiology, diagnosis and treatment. *J Psychosom Res* 1999; 46: 315–333. 1999/05/26.

57. Zeluf G, Dhejne C, Orre C, *et al.* Health, disability and quality of life among trans people in Sweden-a web-based survey. *BMC Public Health* 2016; 16: 903.

58. Poguri M and Sarkar S. A pilot study to assess emotional distress and quality of life among transgenders in South India. *Neuropsychiatry (London)* 2016; 6: 22–27.

59. Auer MK, Liedl A, Fuss J, *et al.* High impact of sleeping problems on quality of life in transgender individuals: a cross-sectional multicenter study. *PLoS One* 2017; 12: e0171640.

60. George A, Janardhana N and Muralidhar D. Quality of life of transgender older adults. *Int J Soc Humaniit Inven* 2015; 4: 7–11.

61. Padula WV, Heru S and Campbell JD. Societal implications of health insurance coverage for medically necessary services in the U.S. transgender population: a cost-effectiveness analysis. *J Gen Intern Med* 2016; 31: 394–401.

62. de Blok CJM, Klaver M, Wiepjes CM, *et al.* Breast development in transwomen after 1 year of cross-sex hormone therapy: results of a prospective multicenter study. *J Clin Endocrinol Metab* 2018; 103: 532–538.

63. Dittrich R, Binder H, Cupisti S, *et al.* Endocrine treatment of male-to-female transsexuals using gonadotropin-releasing hormone agonist. *Exp Clin Endocrinol Diabetes* 2005; 113: 586–592.

64. Meyer WJ III, Webb A, Stuart CA, *et al.* Physical and hormonal evaluation of transsexual patients: a longitudinal study. *Arch Sex Behav* 1986; 15: 121–138.

65. Prior JC, Vigna YM and Watson D. Spironolactone with physiological female steroids for presurgical therapy of male-to-female transsexualism. *Arch Sex Behav* 1989; 18: 49–57.

66. Kanhai RC, Hage JJ, Karim RB, *et al.* Exceptional presenting conditions and outcome of augmentation mammoplasty in male-to-female transsexuals. *Ann Plast Surg* 1999; 43: 476–483.
67. Wierckx K, Gooren L and T’Sjoen G. Clinical review: breast development in trans women receiving cross-sex hormones. J Sex Med 2014; 11: 1240–1247.

68. Bondy CA and Turner Syndrome Study G. Care of girls and women with turner syndrome: a guideline of the turner syndrome study group. J Clin Endocrinol Metab 2007; 92: 10–25.

69. Prior JC. Progesterone is important for the benefits of progesterone in ciswomen. J Clin Endocrinol Metab 2019; 104: 1181–1186.

70. Riggs BL, Khosla S and Melton LJ III. A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res 1998; 13: 763–773.

71. Cauley JA. Estrogen and bone health in men and women. Steroids 2015; 99: 11–15.

72. Fighera TM, da Silva E, Lindenauf JD, et al. Impact of cross-sex hormone therapy on bone mineral density and body composition in transwomen. Clin Endocrinol (Oxf) 2018; 88: 856–862.

73. T’Sjoen G, Weyers S, Taes Y, et al. Prevalence of low bone mass in relation to estrogen treatment and body composition in male-to-female transsexual persons. J Clin Densitom 2009; 12: 306–313.

74. Van Caenegem E, Wierckx K, Taes Y, et al. Preservation of volumetric bone density and geometry in trans women during cross-sex hormonal therapy: a prospective observational study. Osteoporos Int 2015; 26: 35–47.

75. Van Caenegem E, Taes Y, Wierckx K, et al. Low bone mass is prevalent in male-to-female transsexual persons before the start of cross-sex hormonal therapy and gonadectomy. Bone 2013; 54: 92–97.

76. Zhu LL, Blair H, Cao J, et al. Blocking antibody to the beta-subunit of FSH prevents bone loss by inhibiting bone resorption and stimulating bone synthesis. Proc Natl Acad Sci U S A 2012; 109: 14574–14579.

77. Khosla S, Melton LJ III and Riggs BL. The unitary model for estrogen deficiency and the pathogenesis of osteoporosis: is a revision needed? J Bone Miner Res 2011; 26: 441–451.

78. van Kesteren P, Lips P, Gooren LJ, et al. Long-term follow-up of bone mineral density and bone metabolism in transsexuals treated with cross-sex hormones. Clin Endocrinol (Oxf) 1998; 48: 347–354.

79. Haraldsen IR, Haug E, Falch J, et al. Cross-sex pattern of bone mineral density in early onset gender identity disorder. Horm Behav 2007; 52: 334–343.

80. Wiepjes CM, de Jongh RT, de Blok CJ, et al. Bone safety during the first ten years of gender-affirming hormonal treatment in transwomen and transmen. J Bone Miner Res 2018; 34: 447–454.

81. Wiepjes CM, Vlot MC, Klaver M, et al. Bone mineral density increases in trans persons after 1 year of hormonal treatment: a multicenter prospective observational study. J Bone Miner Res 2017; 32: 1252–1260.

82. Van Caenegem E and T’Sjoen G. Bone in trans persons. Curr Opin Endocrinol Diabetes Obes 2015; 22: 459–466.

83. Singh-Ospina N, Maraka S, Rodriguez-Gutierrez R, et al. Effect of sex steroids on the bone health of transgender individuals: a systematic review and meta-analysis. J Clin Endocrinol Metab 2017; 102: 3904–3913.

84. Bruder JM, Ma JZ, Basler JW, et al. Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy. Urology 2006; 67: 152–155.

85. Panagiotakopoulos L. Transgender medicine - puberty suppression. Rev Endocr Metab Disord 2018; 19: 221–225.

86. Klink D, Caris M, Heijboer A, et al. Bone mass in young adulthood following gonadotropin-releasing hormone analog treatment and cross-sex hormone treatment in adolescents with gender dysphoria. J Clin Endocrinol Metab 2015; 100: E270–E275.

87. Vlot MC, Klink DT, den Heijer M, et al. Effect of pubertal suppression and cross-sex hormone therapy on bone turnover markers and bone mineral apparent density (BMAD) in transgender adolescents with gender dysphoria. J Clin Endocrinol Metab 2015; 100: E270–E275.

88. Vlot MC, Klink DT, den Heijer M, et al. Effect of pubertal suppression and cross-sex hormone therapy on bone turnover markers and bone mineral apparent density (BMAD) in transgender adolescents with gender dysphoria. J Bone 2017; 95: 11–19.

89. Elamin MB, Garcia MZ, Murad MH, et al. Effect of sex steroid use on cardiovascular risk in transsexual individuals: a systematic review and meta-analyses. Clin Endocrinol (Oxf) 2010; 72: 1–10.
90. Shatzel JJ, Connelly KJ and DeLoughery TG. Thrombotic issues in transgender medicine: a review. *Am J Hematol* 2017; 92: 204–208.

91. van Kesteren PJ, Asscheman H, Megens JA, *et al*. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. *Clin Endocrinol (Oxf)* 1997; 47: 337–342.

92. Defreyne J, Van de Bruaene LDL, Rietzschel E, *et al*. Effects of gender-affirming hormones on lipid, metabolic, and cardiac surrogate blood markers in transgender persons. *Clin Chem* 2019; 65: 119–134.

93. Maraka S, Singh Ospina N, Rodriguez-Gutierrez R, *et al*. Sex steroids and cardiovascular outcomes in transgender individuals: a systematic review and meta-analysis. *J Clin Endocrinol Metab* 2017; 102: 3914–3923.

94. Irwig MS. Cardiovascular health in transgender people. *Rev Endocr Metab Disord* 2018; 19: 243–251.

95. Arnold JD, Sarkodie EP, Coleman ME, *et al*. Incidence of venous thromboembolism in transsexual women receiving oral estradiol. *J Sex Med* 2016; 13: 1773–1777.

96. Asscheman H, Gooren LJ and Eklund PL. Mortality and morbidity in transsexual patients with cross-gender hormone treatment. *Metabolism* 1989; 38: 869–873.

97. De Cuypere G, T’Sjoen G, Beerten R, *et al*. Sexual and physical health after sex reassignment surgery. *Arch Sex Behav* 2005; 34: 679–690.

98. Dhejne C, Lichtenstein P, Boman M, *et al*. Long-term follow-up of transsexual persons undergoing sex reassignment surgery: cohort study in Sweden. *PLoS One* 2011; 6: e16885.

99. Sokoff NJ, Scarbro S, Juarez-Colunga E, *et al*. Health and cardiometabolic disease in transgender adults in the United States: behavioral risk factor surveillance system 2015. *J Endocr Soc* 2018; 2: 349–360.

100. Ott J, Kaufmann U, Bentz EK, *et al*. Incidence of thrombophilia and venous thrombosis in transsexuals under cross-sex hormone therapy. *Fertil Steril* 2010; 93: 1267–1272.

101. Quinn VP, Nash R, Hunkele E, *et al*. Cohort profile: study of transition, outcomes and gender (STRONG) to assess health status of transgender people. *BMJ open* 2017; 7: e018121.

102. Schlatterer K, Yassouridis A, von Werder K, *et al*. A follow-up study for estimating the effectiveness of a cross-gender hormone substitution therapy on transsexual patients. *Arch Sex Behav* 1998; 27: 475–492.

103. Seal LJ, Franklin S, Richards C, *et al*. Predictive markers for mammoplasty and a comparison of side effect profiles in transwomen taking various hormonal regimens. *J Clin Endocrinol Metab* 2012; 97: 4422–4428.

104. Gooren LJ, Wierckx K and Giltay EJ. Cardiovascular disease in transsexual persons treated with cross-sex hormones: reversal of the traditional sex difference in cardiovascular disease pattern. *Eur J Endocrinol* 2014; 170: 809–819.

105. Getahun D, Nash R, Flanders WD, *et al*. Cross-sex hormones and acute cardiovascular events in transgender persons: a cohort study. *Ann Intern Med* 2018; 169: 205–213.

106. Centers for Disease Control and Prevention (US), National Center for Chronic Disease Prevention and Health Promotion (US), *et al.* How tobacco smoke causes disease: the biology and behavioral basis for smoking-attributable disease: a report of the surgeon general. 6, cardiovascular diseases, https://www.ncbi.nlm.nih.gov/books/NBK53012/ (2010, accessed July 22, 2019).

107. Cheng YJ, Liu ZH, Yao FJ, *et al*. Current and former smoking and risk for venous thromboembolism: a systematic review and meta-analysis. *PLoS Med* 2013; 10: e1001515.

108. Enga KF, Braekkan SK, Hansen-Krone IJ, *et al*. Cigarette smoking and the risk of venous thromboembolism: the Tromso study. *J Thromb Haemost* 2012; 10: 2068–2074.

109. Severinsen MT, Kristensen SR, Johnsen SP, *et al*. Smoking and venous thromboembolism: a Danish follow-up study. *J Thromb Haemost* 2009; 7: 1297–1303.

110. Zhang G, Xu X, Su W, *et al*. Smoking and risk of venous thromboembolism: a systematic review. *Southeast Asian J Trop Med Public Health* 2014; 45: 736–745.

111. Myers SC and Safer JD. Increased rates of smoking cessation observed among transgender women receiving hormone treatment. *Endocr Pract* 2017; 23: 32–36.

112. Martinez C, Rikhi R, Haque T, *et al*. Gender identity, hormone therapy, and cardiovascular disease risk. *Curr Probl Cardiol* 2018; pii: S0146-2806(18)30142-7.

113. Auer MK, Cecil A, Roepke Y, *et al*. 12-months metabolic changes among gender dysphoric
individuals under cross-sex hormone treatment: a targeted metabolomics study. Sci Rep 2016; 6: 37005.

114. Deutsch MB, Bhakri V and Kubicek K. Effects of cross-sex hormone treatment on transgender women and men. Obstet Gynecol 2015; 125: 605–610.

115. Elbers JM, Giltay EJ, Teerlink T, et al. Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects. Clin Endocrinol (Oxf) 2003; 58: 562–571.

116. Fernandez JD and Tannock LR. Metabolic effects of hormone therapy in transgender patients. Endocr Pract 2016; 22: 383–388.

117. Fung R, Hellstern-Layefsky M, Tastenhoye C, et al. Differential effects of cyproterone acetate vs spironolactone on serum high-density lipoprotein and prolactin concentrations in the hormonal treatment of transgender women. J Sex Med 2016; 13: 1765–1772.

118. Olson-Kennedy J, Okonta V, Clark LF, et al. Physiologic response to gender-affirming hormones among transgender youth. J Adolesc Health 2018; 62: 397–401.

119. Vita R, Settineri S, Liotta M, et al. Changes in hormonal and metabolic parameters in transgender subjects on cross-sex hormone therapy: a cohort study. Maturitas 2018; 107: 92–96.

120. Wierckx K, Van de Peer F, Verhaeghe E, et al. Short- and long-term clinical skin effects of testosterone treatment in trans men. J Sex Med 2014; 11: 222–229.

121. Elbers JMH, Asscheman H, Seidell JC, et al. Reversal of the sex difference in serum leptin levels upon cross-sex hormone administration in transsexuals. J Clin Endocrinol Metab 1997; 82: 3267–3270.

122. Klaver M, de Mutsert R, Wiepjes CM, et al. Early hormonal treatment affects body composition and body shape in young transgender adolescents. J Sex Med 2018; 15: 251–260.

123. Bockting WO, Miner MH, Swinburne Romine RE, et al. Stigma, mental health, and resilience in an online sample of the US transgender population. Am J Public Health 2013; 103: 943–951.

124. Bradford J, Reisner SL, Honnold JA, et al. Experiences of transgender-related discrimination and implications for health: results from the Virginia transgender health initiative study. Am J Public Health 2013; 103: 1820–1829.

125. Hughto JMW, Reisner SL and Pachankis JE. Transgender stigma and health: a critical review of stigma determinants, mechanisms, and interventions. Soc Sci Med 2015; 147: 222–231.

126. Valentine SE and Shiperd JC. A systematic review of social stress and mental health among transgender and gender non-conforming people in the United States. Clin Psychol Rev 2018; 66: 24–38.

127. Coulter RWS, Jun HJ, Calzo JP, et al. Sexual-orientation differences in alcohol use trajectories and disorders in emerging adulthood: results from a longitudinal cohort study in the United States. Addiction. Epub ahead of print 21 April 2018. DOI: 10.1111/add.14251.

128. Grant JM, Mottet LA, Tanis J, et al. Injustice at every turn: a report of the national transgender discrimination survey. Washington, D.C.: National Center for Transgender Equality and National Gay and Lesbian Task Force, 2011.

129. Jones BA, Haycraft E, Murjan S, et al. Body dissatisfaction and disordered eating in trans people: a systematic review of the literature. Int Rev Psychiatry 2016; 28: 81–94.

130. Auer MK, Ebert T, Pietzner M, et al. Effects of sex hormone treatment on the metabolic syndrome in transgender individuals: focus on metabolic cytokines. J Clin Endocrinol Metab 2018; 103: 790–802.

131. Klaver M, Dekker M, de Mutsert R, et al. Cross-sex hormone therapy in transgender persons affects total body weight, body fat and lean body mass: a meta-analysis. Andrologia 2017; 49: e12660.

132. Klaver M, de Blok CJM, Wiepjes CM, et al. Changes in regional body fat, lean body mass and body shape in trans persons using cross-sex hormonal therapy: results from a multicenter prospective study. Eur J Endocrinol 2018; 178: 165–173.

133. Mueller A, Zoller H, Kronawitter D, et al. Body composition and bone mineral density in male-to-female transsexuals during cross-sex hormone therapy using gonadotrophin-releasing hormone agonist. Exp Clin Endocrinol Diabetes 2011; 119: 95–100.

134. Brown GR and Jones KT. Mental health and medical health disparities in 5135 transgender veterans receiving healthcare in the Veterans health administration: a case-control study. LGBT Health 2016; 3: 122–131.
135. Colorado O. Transparent: the state of transgender health in Colorado, https://one-colorado.org/wp-content/uploads/2017/06/OC_Transparent_Download2mb.pdf (2017, accessed December 2018).

136. Rahman R and Linsenmeyer WR. Caring for transgender patients and clients: nutrition-related clinical and psychosocial considerations. *J Acad Nutr Diet*. Epub ahead of print 22 May 2018. DOI: 10.1016/j.jand.2018.03.006.

137. Smalley KB, Warren JC and Barefoot KN. Differences in health risk behaviors across understudied LGBT subgroups. *Health Psychol* 2016; 35: 103–114.

138. Dekker MJ, Wierckx K, Van Caenegem E, et al. A European network for the investigation of gender incongruence: endocrine part. *J Sex Med* 2016; 13: 994–999.

139. Wiik A, Andersson DP, Brismar TB, et al. Metabolic and functional changes in transgender individuals following cross-sex hormone treatment: design and methods of the GEnder Dysphoria Treatment in Sweden (GETS) study. *Contemp Clin Trials Commun* 2018; 10: 148–153.

140. Dimsdale JE. Psychological stress and cardiovascular disease. *J Am Coll Cardiol* 2008; 51: 1237–1246.

141. Leavy M, Trottmann M, Liedl B, et al. Effects of elevated beta-estradiol levels on the functional morphology of the testis - new insights. *Sci Rep* 2017; 7: 39931.

142. Jindarak S, Nilprapha K, Atikankul T, et al. Spermatogenesis abnormalities following hormonal therapy in transwomen. *Biomed Res Int* 2018; 2018: 7919481.

143. Schneider F, Neuhaus N, Wistuba J, et al. Testicular functions and clinical characterization of patients with gender dysphoria (GD) undergoing sex reassignment surgery (SRS). *J Sex Med* 2015; 12: 2190–2200.

144. De Roo C, Tileman K, T’Sjoen G, et al. Fertility options in transgender people. *Int Rev Psychiatry* 2016; 28: 112–119.

145. Auer MK, Fuss J, Nieder TO, et al. Desire to have children among transgender people in Germany: a cross-sectional multi-center study. *J Sex Med* 2018; 15: 757–767.

146. Motmans J, Meier P and T’Sjoen G. De levenskwaliteit van transgender personen in Vlaanderen. *Antwerpen: Steunpunt Gelijkheidsbeleid* 2011.

147. Nahata L, Tishelman AC, Caltablotta NM, et al. Low fertility preservation utilization among transgender youth. *J Adolesc Health* 2017; 61: 40–44.

148. Wierckx K, Stuyver I, Weyers S, et al. Sperm freezing in transsexual women. *Arch Sex Behav* 2012; 41: 1069–1071.

149. De Sutter P, Kira K, Verschoor A, et al. The desire to have children and the preservation of fertility in transsexual women: a survey. *Int J Transgenderism* 2002; 6: 3–97.

150. Motmans J, de Boilley I and Debuinne S. Leven als transgender in België: de sociale en juridische situatie van transgender personen in kaart gebracht. *Brussel: Instituut voor de gelijkheid van vrouwen en mannen* 2009.

151. Mattawanon N, Spencer JB, Schirmer DA III, et al. Fertility preservation options in transgender people: a review. *Rev Endocr Metab Disord* 2018; 19: 231–242.

152. T’Sjoen G, Van Caenegem E and Wierckx K. Transgenderism and reproduction. *Curr Opin Endocrinol Diabetes Obes* 2013; 20: 575–579.

153. Tishelman AC, Sutter ME, Chen D, et al. Health care provider perceptions of fertility preservation barriers and challenges with transgender patients and families: qualitative responses to an international survey. *J Assist Reprod Genet*. Epub ahead of print 3 January 2019. DOI: 10.1007/s10815-018-1395-y.

154. Light AD, Obedin-Maliver J, Sevelius JM, et al. Transgender men who experienced pregnancy after female-to-male gender transitioning. *Obstet Gynecol* 2014; 124: 1120–1127.

155. Poteat T, Scheim A, Xavier J, et al. Global epidemiology of HIV infection and related syndemics affecting transgender people. *J Acquir Immune Defic Syndr* 2016; 72(Suppl. 3): S210–S219.

156. MacCarthy S, Poteat T, Xia ZY, et al. Current research gaps: a global systematic review of HIV and sexually transmissible infections among transgender populations. *Sexual Health* 2017; 14: 456–468.

157. Van Schuylenbergh J, Motmans J and Coene G. Transgender and non-binary persons and sexual risk: a critical review of 10 years of research from a feminist intersectional perspective. *Critical Social Policy* 2018; 38: 121–142.

158. Becasen JS, Denard CL, Mullins MM, et al. Estimating the prevalence of HIV and sexual behaviors among the US transgender population: a systematic review and meta-analysis, 2006-2017. *Am J Public Health* 2018: e1–e8.
159. Herbst JH, Jacobs ED, Finlayson TJ, et al. Estimating HIV prevalence and risk behaviors of transgender persons in the United States: a systematic review. *AIDS Behav* 2008; 12: 1–17.

160. Feldman J, Romine RS and Bockting WO. HIV risk behaviors in the U.S. transgender population: prevalence and predictors in a large internet sample. *J Homosex* 2014; 61: 1558–1588.

161. Center for disease control and Prevention. *HIV Surveillance Report*, 2016, 2017.

162. Center for disease control and Prevention. *HIV Surveillance Report*, 2017, 2018.

163. Center for disease control and Prevention. *Estimated HIV incidence and prevalence in the United States, 2010–2015. HIV Surveillance Supplemental Report*, 2018.

164. Satcher Johnson A, Song R and Hall HI. Estimated HIV incidence, prevalence, and undiagnosed infections in US States and Washington, DC, 2010–2014. *J Acquir Immune Defic Syndr* 2017; 76: 116–122.

165. Baral SD, Poteat T, Stromdahl S, et al. Worldwide burden of HIV in transgender women: a systematic review and meta-analysis. *Lancet Infect Dis* 2013; 13: 214–222.

166. Guadamuz TE, Wimonsate W, Varangrat A, et al. HIV prevalence, risk behavior, hormone use and surgical history among transgender persons in Thailand. *AIDS Behav* 2011; 15: 650–658.

167. Nemoto T, Iwamoto M, Perngparn U, et al. HIV-related risk behaviors among kathoey (male-to-female transgender) sex workers in Bangkok, Thailand. *AIDS Care* 2012; 24: 210–219.

168. Operario D, Nemoto T, Iwamoto M, et al. Unprotected sexual behavior and HIV risk in the context of primary partnerships for transgender women. *AIDS Behav* 2011; 15: 674–682.

169. Nadal KL, Davidoff KC and Fujii-Doe W. Transgender women and the sex work industry: roots in systemic, institutional, and interpersonal discrimination. *J Trauma Dissociation* 2014; 15: 169–183.

170. Nuttbrock LA and Hwangh SJ. Ethnicity, sex work, and incident HIV/STI among transgender women in New York city: a 3-year prospective study. *AIDS Behav* 2017; 21: 3328–3335.

171. Clark H, Babu AS, Wiewel EW, et al. Diagnosed HIV infection in transgender adults and adolescents: results from the national HIV surveillance system, 2009–2014. *AIDS Behav* 2017; 21: 2774–2783.

172. Longman Marcellin R, Bauer GR and Scheim AI. Intersecting impacts of transphobia and racism on HIV risk among trans persons of colour in Ontario, Canada. *Ethnicity and Inequalities in Health and Social Care* 2013; 6: 97–107.

173. Radix A, Sevelius J and Deutsch MB. Transgender women, hormonal therapy and HIV treatment: a comprehensive review of the literature and recommendations for best practices. *J Int AIDS Soc* 2016; 19: 20810.

174. Hoornenborg E, Krakower DS, Prins M, et al. Pre-exposure prophylaxis for MSM and transgender persons in early adopting countries. *AIDS* 2017; 31: 2179–2191.

175. Anderson PL, Reirden D and Casillo-Mancilla J. Pharmacologic considerations for preexposure prophylaxis in transgender women. *J Acquir Immune Defic Syndr* 2016; 72(Suppl. 3): S230–S234.

176. Sevelius JM, Deutsch MB and Grant R. The future of PrEP among transgender women: the critical role of gender affirmation in research and clinical practices. *J Int AIDS Soc* 2016; 19: 21105.

177. Eismann J, Heng YJ, Fleischmann-Rose K, et al. Interdisciplinary management of transgender individuals at risk for breast cancer: case reports and review of the literature. *Clin Breast Cancer* 2019; 9: e12–e19.

178. Gooren L, Bowers M, Lips P, et al. Five new cases of breast cancer in transsexual persons. *Andrologia* 2015; 47: 1202–1205.

179. Gooren LJ, van Trotsenburg MA, Giltay EJ, et al. Breast cancer development in transsexual subjects receiving cross-sex hormone treatment. *Clin Breast Cancer* 2013; 10: 3129–3134.

180. de Blok CJM, Wiepjes CM, Nota NM, et al. Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands. *BMJ* 2019; 365: 11652.

181. Brown GR and Jones KT. Incidence of breast cancer in a cohort of 5,135 transgender veterans. *Breast Cancer Res Treat* 2015; 149: 191–198.

182. Phillips J, Fein-Zachary VJ, Mehta TS, et al. Breast imaging in the transgender patient. *AJR Am J Roentgenol* 2014; 202: 1149–1156.

183. Sonnenblick EB, Shah AD, Goldstein Z, et al. Breast imaging of transgender individuals: a review. *Curr Radiol Rep* 2018; 6: 1.

184. Pivo S, Montes J, Schwartz S, et al. Breast cancer risk assessment and screening in...
transgender patients. Clin Breast Cancer 2017; 17: e225–e227.

185. Miglioretti DL, Rutter CM, Geller BM, et al. Effect of breast augmentation on the accuracy of mammography and cancer characteristics. JAMA 2004; 291: 442–450.

186. Evans A, Trimboi RM, Athanasiou A, et al. Breast ultrasound: recommendations for information to women and referring physicians by the European society of breast imaging. Insights Imaging 2018; 9: 449–461.

187. van Kesteren P, Meinhardt W, van der Valk P, et al. Effects of estrogens only on the prostates of aging men. J Urol 1996; 156: 1349–1353.

188. Gooren L and Morgentaler A. Prostate cancer incidence in orchidectomised male-to-female transsexual persons treated with oestrogens. Andrologia 2014; 46: 1156–1160.

189. McFarlane T, Zajac JD and Cheung AS. Gender-affirming hormone therapy and the risk of sex hormone-dependent tumours in transgender individuals: a systematic review. Clin Endocrinol (Oxf) 2018; 89: 700–711.

190. Deebel NA, Morin JP, Autorino R, et al. Prostate cancer in transgender women: incidence, etiopathogenesis, and management challenges. Urology 2017; 110: 166–171.

191. Ingham MD, Lee RJ, MacDermed D, et al. Prostate cancer in transgender women. Urol Oncol 2018; 36: 518–525.

192. Joint R, Chen ZE and Cameron S. Breast and reproductive cancers in the transgender population: a systematic review. BJOG 2018; 125: 1505–1512.

193. Ter Wengel PV, Martin E, Gooren L, et al. Meningiomas in three male-to-female transgender subjects using oestrogens/progestogens and review of the literature. Andrologia 2016; 48: 1130–1137.

194. Mancini I, Rotilio A, Coati I, et al. Presentation of a meningioma in a transwoman after nine years of cyproterone acetate and estradiol intake: case report and literature review. Gynecol Endocrinol 2018; 34: 456–459.

195. Defreyne J, Nota N, Pereira C, et al. Transient elevated serum prolactin in trans women is caused by cyproterone acetate treatment. LGBT Health 2017; 4: 328–336.

196. Kobori Y, Suzuki K, Iwahata T, et al. Mature testicular teratoma with positive estrogen receptor beta expression in a transgendered individual on cross-sex hormonal therapy: a case report. LGBT Health 2015; 2: 81–83.

197. Bultynck C, Pas C, Defreyne J, et al. Self-perception of voice in transgender persons during cross-sex hormone therapy. Laryngoscope 2017; 127: 2796–2804.

198. Dacakis G. The role of voice therapy in male-to-female transsexuals. Curr Opin Otolaryngol Head Neck Surg 2002; 10: 173–177.

199. Oates J and Dacakis G. Voice change in transsexuals. Venereology 1997; 10: 178–187.

200. Davies S, Papp VG and Antoni C. Voice and communication change for gender nonconforming individuals: giving voice to the person inside. Int J Transgenderism 2015; 16: 117–159.

201. McNeill EJ, Wilson JA, Clark S, et al. Perception of voice in the transgender client. J Voice 2008; 22: 727–733.

202. Pasricha N, Dacakis G and Oates J. Communicative satisfaction of male-to-female transsexuals. Logoped Phoniatr Vocal 2008; 33: 25–34.

203. T’Sjoen G, Moerman M, van Borsel J, et al. Impact of voice in transsexuals. Int J Transgenderism 2006; 9: 1–7.

204. Schwarz K, Fontanari AMV, Costa AB, et al. Perceptual-auditory and acoustical analysis of the voices of transgender women. J Voice 2018; 32: 602–608.

205. Meister J, Kuhn H, Shehata-Dieler W, et al. Perceptual analysis of the male-to-female transgender voice after glottoplasty-the telephone test. Laryngoscope 2017; 127: 875–881.

206. Hancock AB. An ICF perspective on voice-related quality of life of American transgender women. J Voice 2017; 31: 115 e111–115 e118.

207. Morrison SD, Crowe CS, Rashidi V, et al. Beyond phonosurgery: considerations for patient-reported outcomes and speech therapy in transgender vocal feminization. Otolaryngol Head Neck Surg 2017; 157: 349.

208. Gao Y, Maurer T and Mirmirani P. Understanding and addressing hair disorders in transgender individuals. Am J Clin Dermatol 2018; 19: 517–527.

209. Ginsberg BA. Dermatologic care of the transgender patient. Int J Womens Dermatol 2017; 3: 65–67.

210. Hermosura Almazan T and Kabigting FD. Dermatologic care of the transgender patient. Dermatol Online J 2016; 22
211. Katz KA and Furnish TJ. Dermatology-related epidemiologic and clinical concerns of men who have sex with men, women who have sex with women, and transgender individuals. *Arch Dermatol* 2005; 141: 1303–1310.

212. Giltay EJ and Gooren LJ. Effects of sex steroid deprivation/administration on hair growth and skin sebum production in transsexual males and females. *J Clin Endocrinol Metab* 2000; 85: 2913–2921.

213. Gooren L. Hormone treatment of the adult transsexual patient. *Horn Res* 2005; 64(Suppl. 2): 31–36.

214. Harder Y, Erni D and Banic A. Squamous cell carcinoma of the penile skin in a neovagina 20 years after male-to-female reassignment. *Br J Plast Surg* 2002; 55: 449–451.

215. Fox LP, Geyer AS, Husain S, et al. Mycobacterium abscessus cellulitis and multifocal abscesses of the breasts in a transsexual from illicit intramammary injections of silicone. *J Am Acad Dermatol* 2004; 50: 450–454.

216. Tachamo N, Donato A, Timilsina B, et al. Hypercalcemia associated with cosmetic injections: a systematic review. *Eur J Endocrinol* 2018; 178: 425–430.

217. Gaber Y. Secondary lymphoedema of the lower leg as an unusual side-effect of a liquid silicone injection in the hips and buttocks. *Dermatology* 2004; 208: 342–344.

218. Chasan PE. The history of injectable silicone fluids for soft-tissue augmentation. *Plast Reconstr Surg* 2007; 120: 2034–2040; discussion 2041–2033.

219. Stypek A, Bayers S, Beer M, et al. Nonmedical-grade injections of permanent fillers: medical and medicolegal considerations. *J Clin Aesthet Dermatol* 2013; 6: 22–29.

220. Ettner R, Monstrey S and Coleman E. *Principles of transgender medicine and surgery*. New York and London: Routledge, 2016.

221. Schroeter CA, Groenewegen JS, Reineke T, et al. Ninety percent permanent hair reduction in transsexual patients. *Ann Plast Surg* 2003; 51: 243–248.

222. Rametti G, Carrillo B, Gomez-Gil E, et al. White matter microstructure in female to male transsexuals before cross-sex hormonal treatment. A diffusion tensor imaging study. *J Psychiatr Res* 2011; 45: 199–204.

223. Rametti G, Carrillo B, Gomez-Gil E, et al. The microstructure of white matter in male to female transsexuals before cross-sex hormonal treatment. A DTI study. *J Psychiatr Res* 2011; 45: 949–954.

224. Kranz GS, Hahn A, Kaufmann U, et al. White matter microstructure in transsexuals and controls investigated by diffusion tensor imaging. *J Neurosci* 2014; 34: 15466–15475.

225. Kranz GS, Seiger R, Kaufmann U, et al. Effects of sex hormone treatment on white matter microstructure in individuals with gender dysphoria. *Neuroimage* 2017; 150: 60–67.

226. Hahn A, Kranz GS, Kublbock M, et al. Structural connectivity networks of transgender people. *Cereb Cortex* 2015; 25: 3527–3534.

227. Seiger R, Hahn A, Hummer A, et al. Subcortical gray matter changes in transgender subjects after long-term cross-sex hormone administration. *Psychoneuroendocrinology* 2016; 74: 371–379.

228. Mueller SC, Landre L, Wierckx K, et al. A structural magnetic resonance imaging study in transgender persons on cross-sex hormone therapy. *Neuroendocrinology* 2017; 105: 123–130. 2016/08/05. DOI: 10.1159/000448787.

229. Kreukels BP and Guillamon A. Neuroimaging studies in people with gender incongruence. *Int Rev Psychiatry* 2016; 28: 120–128.

230. Mueller SC, De Cuypere G and T’Sjoen G. Transgender research in the 21st century: a selective critical review from a neurocognitive perspective. *Am J Psychiatry* 2017; 174: 1155–1162.

231. Fuss J, Hellweg R, Van Caenegem E, et al. Cross-sex hormone treatment in male-to-female transsexual persons reduces serum brain-derived neurotrophic factor (BDNF). *Eur Neuropsychopharmacol* 2015; 25: 95–99.

232. Nguyen HB, Chavez AM, Lipner E, et al. Gender-affirming hormone use in transgender individuals: impact on behavioral health and cognition. *Curr Psychiatry Rep* 2018; 20: 110.

233. Wanta JW and Unger CA. Review of the transgender literature: where do we go from here? *Transgend Health* 2017; 2: 119–128.

234. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the women’s health initiative randomized controlled trial. *JAMA* 2004; 291: 1701–1712.

235. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the women’s health
initiative randomized trials. *JAMA* 2013; 310: 1353–1368.

236. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial. *JAMA* 2002; 288: 321–333.

237. Stefanick ML, Cochrane BB, Hsia J, et al. The women’s health initiative postmenopausal hormone trials: overview and baseline characteristics of participants. *Ann Epidemiol* 2003; 13: S78–S86.

238. Blosnich JR, Brown GR, Shipherd JC, et al. Prevalence of gender identity disorder and suicide risk among transgender veterans utilizing Veterans health administration care. *Am J Public Health* 2013; 103: e27–e32.

239. Frayne SM, Yano EM, Nguyen VQ, et al. Gender disparities in Veterans health administration care: importance of accounting for veteran status. *Medical care* 2008; 46: 549–553.

240. Shipherd JC, Mizock L, Mauguen S, et al. Male-to-female transgender Veterans and VA health care utilization. *Intern J Sex Health* 2012; 24: 78–87.

241. Blosnich JR, Brown GR, Wojcio S, et al. Mortality among Veterans with transgender-related diagnoses in the Veterans health administration, FY2000-2009. *LGBT Health* 2014; 1: 269–276.